# Section 32 Adolescent and Young Adult Cancer by Site Incidence, Survival and Mortality

Tumors affecting adolescents and young adults often differ from those affecting pediatric and older adult populations<sup>1</sup>. For this reason, a classification scheme has been proposed for tumors diagnosed in adolescents and young adults<sup>2</sup>. This classification scheme was updated based on site and histology codes of the International Classification of Diseases for Oncology, Third Edition<sup>3</sup>. Effective 2001, all cases reported to SEER were required to have an ICD-O-3 histology and behavior code and all previous cases were converted to ICD-O-3<sup>4</sup>. In addition, although benign brain tumors have also been reported to SEER since 2004, not enough time has elapsed to present rates and trend data for these tumors. These site / histology groupings, however, are not comparable with the groupings of ICD-10 for mortality. Therefore, for incidence and mortality comparisons, the SEER site recode as described in the appendix was used<sup>5</sup>. In this chapter, the incidence of malignant cancers in adolescent and young adults, 15 to 39 years of age, are presented based on the 2 different classification schemes described above.

### REFERENCES:

- 1. The distinctive biology of cancer in adolescents and young adults. Bleyer A, Barr R, Hayes-Lattin B, et al. Nat Rev Cancer. 2008; 8: 288-98.
- 2. Barr RD, Holowaty EJ, Birch JM. Classification schemes for tumors diagnosed in adolescents and young adults. Cancer 2006; 106: 1425-1430.
- International Classification of Diseases for Oncology, Third Edition Edited by A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, D.M. Parkin and S. Whelan. World Health Organization. Geneva, Switzerland, 2000. 240 pp.
- National Cancer Institute SEER Conversion Programs.
   Worldwide web: (<a href="http://seer.cancer.gov/tools/conversion">http://seer.cancer.gov/tools/conversion</a>/) Accessed May 28, 2008.
- National Cancer Institute Cancer Statistics Review 1975-2005. Appendix. Worldwide web: (<a href="http://seer.cancer.gov/csr/1975\_2005/results\_merged/topic\_siterecode.pdf">http://seer.cancer.gov/csr/1975\_2005/results\_merged/topic\_siterecode.pdf</a>.) Accessed May 28, 2008.

Table 32.1 Age-Adjusted SEER Incidence  $^{\rm a}$ , by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup> All Races, 2002-2006

	Ages 0-14		Ages 15-39		Ages	s 40+	
Site	Male	Female	Male	Female	Male	Female	
All Sites Combined	16.1	14.0	50.9	80.3	1209.1	876.0	
1. LEUKEMIAS	5.5	4.5	3.4	2.4	31.0	17.8	
1.1 Acute lymphoid leukemia	4.4	3.5	1.2	0.6	1.2	1.0	
1.2 Acute myeloid leukemia	0.8	0.8	1.2	1.1	9.5	6.0	
1.3 Chronic myeloid leukemia	0.0	0.1	0.6	0.4	2.6	1.7	
1.4 Other and unspecified leukemias	0.2	0.2	0.4	0.2	17.7	9.1	
2. LYMPHOMAS	1.8	1.0	8.5	6.8	53.8	37.8	
2.1 Non-Hodgkin Lymphoma	1.1	0.6	4.8	3.1	50.0	35.3	
2.2 Hodgkin Lymphoma	0.7	0.4	3.6	3.7	3.9	2.5	
11.							
3. CNS, INTRACRANIAL, INTRASPINAL	3.2	2.8	3.1	2.5	13.5	9.0	
3.1 Astrocytoma	1.5	1.5	1.6	1.3	10.5	6.5	
3.1.1 Specified low-grade astrocytic tumors	1.1	1.1	0.4	0.4	0.3	0.2	
3.1.2 Glioblastoma and anaplastic astrocytoma	0.2	0.2	0.8	0.6	9.4	5.7	
3.1.3 Astrocytoma, NOS	0.2	0.2	0.4	0.3	0.7	0.5	
3.2 Other glioma	0.5	0.5	0.9	0.7	1.7	1.3	
3.3 Ependymoma	0.3	0.3	0.2	0.2	0.3	0.3	
3.4 Medulloblastoma and other PNET	0.7	0.5	0.2	0.2	0.1	0.1	
3.4.1 Medulloblastoma	0.4	0.3	0.1	0.1	0.0	0.0	
3.4.2 Supratentorial PNET	0.3	0.2	0.1	0.1	0.1	0.0	
3.5 Other specified intracranial and intraspinal neoplasms	0.1	0.1	0.1	0.1	0.3	0.3	
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	0.0	0.0	0.7	0.6	
4. OSSEOUS & CHONDROMATOUS NEPOLASMS	0.8	0.8	1.0	0.8	1.4	1.0	
4.1 Osteosarcoma	0.4	0.4	0.5	0.3	0.3	0.2	
4.2 Chondrosarcoma	0.0	_	0.2	0.2	0.7	0.5	
4.3 Ewing tumor	0.3	0.3	0.3	0.2	0.1	0.1	
4.4 Other specified and unspecified bone tumors	0.0	-	0.1	0.1	0.3	0.2	
5. SOFT TISSUE SARCOMAS	1.0	0.9	3.4	2.3	12.2	8.8	
5.1 Fibromatous neoplasms	0.1	0.1	0.7	0.8	3.4	2.1	
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	0.1	0.2	0.2	
5.3 Other specified soft tissue sarcoma	0.3	0.3	2.6	1.4	8.7	6.6	
5.3.1 Specified soft tissue sarcoma	0.2	0.2	2.3	1.2	6.9	5.2	
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.2	0.2	1.1	1.1	5.1	5.0	
5.3.1.2 Kaposi sarcoma	_	-	1.2	0.0	1.8	0.2	
5.3.2 Unspecified soft tissue sarcoma	0.1	0.1	0.3	0.2	1.8	1.3	
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	0.5	0.6	10.3	1.0	4.1	0.2	
6.1 Germ cell and trophoblastic neoplasms of gonads	0.3	0.3	9.8	0.7	4.0	0.1	
6.2 Germ cell and trophoblastic neoplasms of	0.3	0.3	0.5	0.7	0.2	0.1	
nongonadal sites	0.3	0.5	0.5	0.3	0.2	· · ·	
6.2.1 Intracranial sites	0.2	0.1	0.2	0.0	_	_	
6.2.2 Other nongonadal sites	0.1	0.2	0.3	0.3	0.2	0.1	
	0.1	J. 2	0.5	0.5	0.2	· · <u>-</u>	

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups -

Census P25-1130).

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.1 - continued

## Age-Adjusted SEER Incidence $^{\rm a}$ , by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup> All Races, 2002-2006

	Ages	0-14	Ages	15-39	Ages	s 40+
Site	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	0.2	0.2	5.7	9.5	58.9	32.7
7.1 Melanoma	0.2	0.2	5.5	9.4	55.4	30.8
7.2 Skin carcinomas	-	-	0.1	0.1	3.6	1.9
8. CARCINOMAS (excluding skin)	0.3	0.6	14.5	53.5	975.6	724.9
8.1 Thyroid carcinoma	0.1	0.3	2.7	13.0	9.1	22.1
8.2 Other carcinoma of head and neck	0.1	0.1	1.7	1.4	50.0	16.4
8.2.1 Nasopharyngeal carcinoma	0.0	-	0.3	0.2	1.9	0.7
8.2.2 Other sites in lip, oral cavity and pharynx	-	0.1	1.2	1.0	31.9	12.0
8.2.3 Nasal cavity, middle ear, sinuses,	-	-	0.3	0.2	16.2	3.8
larynx, other ill-defined head/neck						
8.3 Carcinoma of trachea, bronchus, and lung	-	-	1.0	1.2	167.3	113.0
8.4 Carcinoma of breast	-	-	0.1	19.9	2.6	267.5
8.5 Carcinoma of genitourinary tract	-	0.1	2.8	12.6	493.6	134.4
8.5.1 Carcinoma of kidney	-	0.0	1.6	1.1	37.9	18.7
8.5.2 Carcinoma of bladder	-	-	0.9	0.4	84.5	20.9
8.5.3 Carcinoma of gonads	-	-	0.0	1.8	0.0	25.3
8.5.4 Carcinoma of cervix and uterus	-	-	-	8.8	-	59.8
<pre>8.5.5 Carcinoma of other and ill-defined sites,     genitourinary tract</pre>	-	-	0.3	0.4	371.1	9.8
8.6 Carcinoma of gastrointestinal tract	0.1	0.1	5.6	4.8	232.3	152.8
8.6.1 Carcinoma of colon and rectum	_	_	3.5	3.2	130.7	98.4
8.6.2 Carcinoma of stomach	-	-	0.7	0.6	23.6	11.3
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.0	0.0	0.5	0.2	21.8	7.4
8.6.4 Carcinoma of pancreas	-	-	0.4	0.4	26.8	20.9
8.6.5 Carcinoma of other and ill-defined sites,	-	-	0.5	0.3	29.4	14.8
gastrointestinal tract		0 0		0 6	00 5	10.6
8.7 Carcinoma of other and ill-defined sites, NOS	-	0.0	0.6	0.6	20.7	18.6
8.7.1 Adrenocortical carcinoma	_	<del>-</del> ,	0.0	0.1	0.3	0.3
8.7.2 Carcinoma of other and ill-defined sites, NOS	_	-	0.5	0.6	20.4	18.4
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	2.7	2.5	0.7	1.1	24.6	19.6
9.1 Other pediatric and embryonal tumors, NOS	2.6	2.3	0.1	0.1	0.2	0.2
9.1.1 Wilms tumor	0.6	0.7	_	-	-	0.0
9.1.2 Neuroblastoma	1.0	1.0	0.0	_	_	_
9.1.3 Other pediatric and embryonal tumors, NOS	1.0	0.7	0.1	0.0	0.2	0.1
9.2 Other specified neoplasms, NOS	0.1	0.2	0.6	1.0	24.4	19.4
9.2.1 Paraganglioma and glomus tumors	-	-	0.0	0.0	0.1	0.1
9.2.2 Other specified gonadal tumors	-	-	0.0	0.2	0.0	0.4
9.2.3 Myeloma, mast cell, miscellaneous	0.1	0.1	0.3	0.2	17.5	11.2
lymphoreticular neoplasms, NOS						
9.2.4 Other specified neoplasms, NOS	_	_	0.2	0.6	6.7	7.8
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.2	0.4	33.9	24.4

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups -

Census P25-1130).

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.2 Age-Adjusted SEER Incidence  $^{\rm a}$ , by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup> White, 2002-2006

	Ages	s 0-14	Ages	15-39	Ages	s 40+
Site	Male	Female	Male	Female	Male	Female
All Sites Combined	16.9	14.6	54.2	83.9	1211.8	900.6
1. LEUKEMIAS	5.9	4.8	3.6	2.5	32.5	18.4
1.1 Acute lymphoid leukemia	4.8	3.9	1.4	0.7	1.2	1.0
1.2 Acute myeloid leukemia	0.8	0.7	1.2	1.2	9.8	6.2
1.3 Chronic myeloid leukemia	-	0.1	0.6	0.4	2.6	1.7
1.4 Other and unspecified leukemias	0.2	0.1	0.4	0.2	18.8	9.5
2. LYMPHOMAS	1.8	1.0	8.7	7.1	56.3	39.7
2.1 Non-Hodgkin Lymphoma	1.1	0.6	4.8	3.0	52.2	37.0
2.2 Hodgkin Lymphoma	0.7	0.5	3.9	4.0	4.1	2.7
3. CNS, INTRACRANIAL, INTRASPINAL	3.4	2.9	3.5	2.8	14.8	9.8
3.1 Astrocytoma	1.6	1.6	1.8	1.5	11.6	7.2
3.1.1 Specified low-grade astrocytic tumors	1.2	1.2	0.5	0.5	0.4	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.2	0.2	0.9	0.7	10.4	6.4
3.1.3 Astrocytoma, NOS	0.2	0.2	0.5	0.3	0.8	0.6
3.2 Other glioma	0.6	0.5	1.0	0.8	1.8	1.4
3.3 Ependymoma	0.3	0.2	0.2	0.2	0.3	0.3
3.4 Medulloblastoma and other PNET	0.8	0.5	0.3	0.2	0.1	0.1
3.4.1 Medulloblastoma	0.5	0.3	0.1	0.1	0.0	0.0
3.4.2 Supratentorial PNET	0.4	0.2	0.1	0.1	0.1	0.0
3.5 Other specified intracranial and intraspinal	0.1	0.1	0.1	0.1	0.3	0.3
neoplasms						
3.6 Unspecified intracranial and intraspinal	_	_	0.1	0.0	0.7	0.6
neoplasms						
4. OSSEOUS & CHONDROMATOUS NEPOLASMS	0.9	0.8	1.1	0.9	1.5	1.1
4.1 Osteosarcoma	0.4	0.4	0.4	0.3	0.3	0.2
4.2 Chondrosarcoma	_	_	0.2	0.2	0.8	0.5
4.3 Ewing tumor	0.4	0.3	0.3	0.3	0.1	0.1
4.4 Other specified and unspecified bone tumors	-	-	0.1	0.1	0.3	0.2
5. SOFT TISSUE SARCOMAS	1.0	0.9	3.1	2.2	12.4	8.7
5.1 Fibromatous neoplasms	0.1	0.1	0.6	0.7	3.5	2.0
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	0.1	0.2	0.1
5.3 Other specified soft tissue sarcoma	0.3	0.3	2.3	1.4	8.8	6.5
5.3.1 Specified soft tissue sarcoma	0.2	0.2	2.0	1.2	6.9	5.2
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.2	0.2	1.1	1.2	5.3	5.0
5.3.1.2 Kaposi sarcoma	_	_	1.0	_	1.7	0.2
5.3.2 Unspecified soft tissue sarcoma	0.1	0.1	0.3	0.2	1.9	1.3
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	0.6	0.6	12.3	0.9	4.8	0.2
6.1 Germ cell and trophoblastic neoplasms of gonads	0.2	0.4	11.8	0.7	4.6	0.1
6.2 Germ cell and trophoblastic neoplasms of	0.4	0.3	0.5	0.7	0.2	0.1
nongonadal sites	0.1	0.5	0.5	0.0	ŭ.2	0.1
6.2.1 Intracranial sites	0.2	0.1	0.2	0.0	_	_
6.2.2 Other nongonadal sites	0.1	0.2	0.4	0.2	0.2	0.1

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups -

Census P25-1130).

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.2 - continued

### Age-Adjusted SEER Incidence<sup>a</sup>, by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup> White, 2002-2006

		0-14	Ages	15-39	Ages	40+	
Site	Male	Female	Male	Female	Male	Female	
7. MELANOMA AND SKIN CARCINOMAS	0.3	0.3	6.8	11.6	67.7	38.0	
7.1 Melanoma	0.3	0.3	6.7	11.5	63.8	36.0	
7.2 Skin carcinomas	-	-	0.1	0.1	3.9	2.0	
8. CARCINOMAS (excluding skin)	0.3	0.7	14.3	54.6	964.3	741.7	
8.1 Thyroid carcinoma	0.1	0.3	2.9	14.1	9.7	22.9	
8.2 Other carcinoma of head and neck	0.1	0.1	1.6	1.2	50.5	16.7	
8.2.1 Nasopharyngeal carcinoma	-	-	0.1	0.1	1.2	0.4	
8.2.2 Other sites in lip, oral cavity and pharynx	-	0.1	1.2	1.0	33.2	12.4	
8.2.3 Nasal cavity, middle ear, sinuses,	-	-	0.3	0.2	16.1	3.9	
larynx, other ill-defined head/neck							
8.3 Carcinoma of trachea, bronchus, and lung	_	_	1.0	1.2	167.1	117.9	
8.4 Carcinoma of breast	_	_	0.0	19.7	2.6	277.0	
8.5 Carcinoma of genitourinary tract	_	0.1	2.9	13.1	487.8	140.3	
8.5.1 Carcinoma of kidney	_	_	1.6	1.1	38.9	19.3	
8.5.2 Carcinoma of bladder	_	_	1.0	0.4	91.7	22.3	
8.5.3 Carcinoma of gonads	_	-	0.1	1.8	0.0	26.9	
8.5.4 Carcinoma of cervix and uterus	_	_	-	9.2	_	61.7	
8.5.5 Carcinoma of other and ill-defined sites,	_	-	0.3	0.5	357.1	10.2	
genitourinary tract							
8.6 Carcinoma of gastrointestinal tract	0.1	0.1	5.3	4.6	225.6	147.9	
8.6.1 Carcinoma of colon and rectum	-	-	3.5	3.1	130.0	97.2	
8.6.2 Carcinoma of stomach	-	-	0.6	0.5	21.0	9.6	
8.6.3 Carcinoma of liver and intrahepatic bile ducts	_	-	0.3	0.2	18.4	6.2	
8.6.4 Carcinoma of pancreas	_	-	0.4	0.4	26.7	20.5	
8.6.5 Carcinoma of other and ill-defined sites,	-	-	0.5	0.3	29.5	14.3	
gastrointestinal tract							
8.7 Carcinoma of other and ill-defined sites, NOS	_	-	0.5	0.6	20.9	18.9	
8.7.1 Adrenocortical carcinoma	-	-	0.0	0.1	0.3	0.3	
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.5	0.5	20.7	18.7	
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	2.8	2.6	0.6	1.0	24.0	18.3	
9.1 Other pediatric and embryonal tumors, NOS	2.7	2.4	0.1	0.1	0.2	0.2	
9.1.1 Wilms tumor	0.6	0.7	-	-	-	_	
9.1.2 Neuroblastoma	1.0	1.0	0.0	-	-	_	
9.1.3 Other pediatric and embryonal tumors, NOS	1.0	0.6	0.1	0.0	0.2	0.1	
9.2 Other specified neoplasms, NOS	0.1	0.2	0.5	0.9	23.8	18.1	
9.2.1 Paraganglioma and glomus tumors	_	_	0.0	0.0	0.1	0.1	
9.2.2 Other specified gonadal tumors	_	_	-	0.1	0.0	0.3	
9.2.3 Myeloma, mast cell, miscellaneous	0.1	0.1	0.3	0.2	16.7	10.2	
lymphoreticular neoplasms, NOS							
9.2.4 Other specified neoplasms, NOS	-	-	0.2	0.6	7.0	7.5	
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.2	0.4	33.5	24.7	

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups -

Census P25-1130).

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.3 Age-Adjusted SEER Incidence  $^{\rm a}$ , by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup> Black, 2002-2006

	Ages	s 0-14	Ages	15-39	Ages	s 40+
Site	Male	Female	Male	Female	Male	Female
All Sites Combined	12.0	11.1	40.5	67.7	1433.3	865.6
1. LEUKEMIAS	3.4	2.5	3.0	2.1	25.1	15.0
1.1 Acute lymphoid leukemia	2.3	1.5	0.7	0.5	1.0	0.9
1.2 Acute myeloid leukemia	0.9	0.8	1.2	0.9	7.3	5.4
1.3 Chronic myeloid leukemia	_	-	0.7	0.5	2.7	1.6
1.4 Other and unspecified leukemias	-	-	0.4	0.2	14.0	7.1
2. LYMPHOMAS	1.7	1.1	9.5	7.2	40.5	27.2
2.1 Non-Hodgkin Lymphoma	1.0	0.6	6.3	3.9	36.7	24.7
2.2 Hodgkin Lymphoma	0.7	0.5	3.2	3.3	3.8	2.5
3. CNS, INTRACRANIAL, INTRASPINAL	2.1	2.4	1.7	1.5	8.3	5.4
3.1 Astrocytoma	1.0	1.1	1.0	0.7	5.7	3.3
3.1.1 Specified low-grade astrocytic tumors	0.6	0.7	0.2	0.2	_	_
3.1.2 Glioblastoma and anaplastic astrocytoma	-	-	0.5	0.3	5.2	2.9
3.1.3 Astrocytoma, NOS	_	_	0.3	-	0.4	0.3
3.2 Other glioma	0.5	0.5	0.4	0.4	1.0	0.7
3.3 Ependymoma	-	0.3	-	-	-	_
3.4 Medulloblastoma and other PNET	0.3	0.4		_	_	_
3.4.1 Medulloblastoma	_	_		_	_	_
3.4.2 Supratentorial PNET	_	_	_	_	_	_
3.5 Other specified intracranial and intraspinal	_	_		_	0.4	0.5
neoplasms						
3.6 Unspecified intracranial and intraspinal	_	_		_	0.9	0.6
neoplasms						
4. OSSEOUS & CHONDROMATOUS NEPOLASMS	0.5	0.7	0.9	0.5	1.0	1.0
4.1 Osteosarcoma	0.4	0.6	0.6	0.4	0.4	0.4
4.2 Chondrosarcoma	-	-	-	-	0.4	0.3
4.3 Ewing tumor	_	_	_	_	-	-
4.4 Other specified and unspecified bone tumors	_	_	_	_	_	_
5. SOFT TISSUE SARCOMAS	1.2	1.0	6.4	3.5	11.6	11.1
5.1 Fibromatous neoplasms	_	-	0.9	1.4	2.6	2.5
5.2 Rhabdomyosarcoma	0.6	0.5	0.2	_	-	0.3
5.3 Other specified soft tissue sarcoma	0.3	0.3	5.2	2.0	8.8	8.3
5.3.1 Specified soft tissue sarcoma	_	-	4.8	1.5	7.0	6.3
5.3.1.1 Specified (excluding Kaposi sarcoma)	-	_	1.2	1.4	4.2	5.9
5.3.1.2 Kaposi sarcoma	-	-	3.6	-	2.8	0.3
5.3.2 Unspecified soft tissue sarcoma	_	-	0.5	0.5	1.8	2.0
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	-	0.5	2.3	0.9	1.1	0.3
6.1 Germ cell and trophoblastic neoplasms of gonads	_	-	2.0	0.5	1.0	-
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	-	0.3	0.3	0.4	-	0.2
6.2.1 Intracranial sites	_	_	_	_	_	_
6.2.2 Other nongonadal sites	_	_	_	0.4	_	0.2
0.2.2 Ocher hongonadar sites	_	_	_	0.4	_	0.2

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups -

Census P25-1130).

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

#### Table 32.3 - continued

### Age-Adjusted SEER Incidence<sup>a</sup>, by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup> Black, 2002-2006

		0-14	Ages	15-39	Ages	40+	
Site	Male	Female	Male	Female	Male	Female	
7. MELANOMA AND SKIN CARCINOMAS	-	-	0.4	0.6	3.8	3.1	
7.1 Melanoma	-	-	0.3	0.5	2.7	2.3	
7.2 Skin carcinomas	-	-	-	-	1.1	0.8	
8. CARCINOMAS (excluding skin)	0.4	0.4	14.6	48.9	1255.8	738.6	
8.1 Thyroid carcinoma	_	_	1.1	6.1	5.4	14.3	
8.2 Other carcinoma of head and neck	_	_	1.8	1.4	62.2	17.1	
8.2.1 Nasopharyngeal carcinoma	-	-	0.5	-	2.2	0.7	
8.2.2 Other sites in lip, oral cavity and pharynx	_	_	0.9	1.0	34.2	11.2	
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	0.3	-	25.8	5.3	
8.3 Carcinoma of trachea, bronchus, and lung	_	_	1.3	1.3	225.7	118.9	
8.4 Carcinoma of breast	_	_	_	22.7	3.6	250.4	
8.5 Carcinoma of genitourinary tract	_	_	3.1	11.3	641.7	119.4	
8.5.1 Carcinoma of kidney	_	_	1.9	1.3	44.6	20.7	
8.5.2 Carcinoma of bladder	_	_	0.6	_	45.4	17.8	
8.5.3 Carcinoma of gonads	_	_	_	1.5	_	18.5	
8.5.4 Carcinoma of cervix and uterus	_	_	_	7.8	_	53.8	
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	0.6	0.6	551.7	8.8	
8.6 Carcinoma of gastrointestinal tract	_	_	6.3	5.2	292.5	197.9	
8.6.1 Carcinoma of colon and rectum	_	_	3.9	3.4	158.1	122.0	
8.6.2 Carcinoma of stomach	_	_	0.6	0.7	35.4	17.9	
8.6.3 Carcinoma of liver and intrahepatic bile ducts	_	_	0.8	0.4	29.0	8.5	
8.6.4 Carcinoma of pancreas	_	_	0.5	0.3	34.1	29.5	
8.6.5 Carcinoma of other and ill-defined sites, qastrointestinal tract	-	-	0.5	0.5	36.0	20.0	
8.7 Carcinoma of other and ill-defined sites, NOS	_	_	0.9	0.9	24.7	20.5	
8.7.1 Adrenocortical carcinoma	_	_	-	-	0.3	0.2	
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.9	0.8	24.5	20.2	
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	2.5	2.4	1.4	1.9	40.1	36.0	
9.1 Other pediatric and embryonal tumors, NOS	2.3	2.3	_	-	_	_	
9.1.1 Wilms tumor	0.6	0.7	_	_	_	_	
9.1.2 Neuroblastoma	0.9	0.9	_	_	_	_	
9.1.3 Other pediatric and embryonal tumors, NOS	0.8	0.6	_	_	_	_	
9.2 Other specified neoplasms, NOS	_	_	1.2	1.8	39.9	35.8	
9.2.1 Paraganglioma and glomus tumors	_	_	_	-	_	_	
9.2.2 Other specified gonadal tumors	_	_	_	0.3	_	0.5	
9.2.3 Myeloma, mast cell, miscellaneous	_	_	0.7	0.7	33.4	23.3	
lymphoreticular neoplasms, NOS							
9.2.4 Other specified neoplasms, NOS	-	-	0.4	0.8	6.3	11.8	
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.3	0.5	45.9	28.1	

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups -

Rates are per 100,000 and are age-adjusted to the 2000 05 Sta Topulation (12 dgs global Census P25-1130).

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 1067; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3 definitions).

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.4

Age-Specific SEER Incidence<sup>a</sup>, by Age Group and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>

All Races, 2002-2006

	Ages 15-19 Ages 20-24		Ages 25-29		Ages 30-34		Ages	35-39		
Site	Male	Female	Male	Female	Male	Female	Male	Female	Male	
All Sites Combined	22.4	19.9	32.8	36.2	45.1	62.2	60.5	103.5	87.4	164.7
1. LEUKEMIAS	3.9	2.2	3.0	2.0	2.7	1.9	3.3	2.6	4.2	3.0
1.1 Acute lymphoid leukemia	2.4	1.0	1.3	0.6	0.8	0.5	0.8	0.6	0.9	0.5
1.2 Acute myeloid leukemia	1.0	0.9	1.0	1.0	1.0	1.0	1.3	1.3	1.5	1.3
1.3 Chronic myeloid leukemia	0.2	0.2	0.4	0.3	0.5	0.3	0.7	0.5	1.1	0.6
1.4 Other and unspecified leukemias	0.2	0.1	0.2	0.1	0.3		0.5	0.2	0.8	0.5
2. LYMPHOMAS	5.2	4.3	7.1	6.5	7.8	7.3	9.3	7.8	12.2	8.2
2.1 Non-Hodgkin Lymphoma	2.3	1.3	2.9	1.9	3.7	2.7	5.5	4.0	8.9	5.4
2.2 Hodgkin Lymphoma	2.9	3.0	4.2	4.6	4.1	4.6	3.8	3.8	3.4	2.8
3. CNS, INTRACRANIAL, INTRASPINAL	2.3	1.9	2.3	2.2	3.1	2.5	3.6	2.7	4.0	3.2
3.1 Astrocytoma	1.3	1.0	1.3	1.3	1.5	1.3	1.7	1.4	2.3	1.6
3.1.1 Specified low-grade astrocytic tumors	0.8	0.6	0.4	0.5	0.3	0.3	0.3	0.3	0.3	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.4	0.2	0.5	0.5	0.7	0.5	1.0	0.7	1.4	1.0
3.1.3 Astrocytoma, NOS	0.2	0.1	0.4	0.3	0.5	0.4	0.4	0.4	0.6	0.3
3.2 Other glioma	0.4	0.4	0.5	0.5	1.1	0.8	1.3	0.9	1.2	1.1
3.3 Ependymoma	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2
3.4 Medulloblastoma and other PNET	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.1	0.1	-
3.4.1 Medulloblastoma	0.1	-	0.2	0.1	-	-	0.1	-	-	-
3.4.2 Supratentorial PNET	0.2	0.2	0.1		0.1	_	-	-	_	-
3.5 Other specified intracranial and intraspinal neoplasms	-				-	_	0.1	-	_	0.1
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-				-	-
4. OSSEOUS & CHONDROMATOUS NEPOLASMS	2.1	1.3	1.2	0.8	0.6	0.7	0.6	0.6	0.8	0.6
4.1 Osteosarcoma	1.2	0.6	0.6	0.4	0.2	0.3	0.1	0.2	0.2	-
4.2 Chondrosarcoma	0.1	-	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.3
4.3 Ewing tumor	0.7	0.5	0.3	0.2	0.2	0.2	0.1	_	0.1	0.1
4.4 Other specified and unspecified bone tumors	0.1	-	-	-	-	-	-	0.1	0.2	-
5. SOFT TISSUE SARCOMAS	1.4	1.5	2.0	1.6	3.1	2.1	4.3	2.7	5.9	3.6
5.1 Fibromatous neoplasms	0.3	0.4	0.4	0.5	0.8	0.9	0.9	1.0	1.0	1.1
5.2 Rhabdomyosarcoma	0.4	0.3	0.2	_	0.1	_	-	-	-	-
5.3 Other specified soft tissue sarcoma	0.8	0.8	1.3	1.0	2.3	1.1	3.3	1.5	4.8	2.4
5.3.1 Specified soft tissue sarcoma	0.6	0.7	1.1	0.8	2.0	0.9	2.9	1.3	4.4	2.0
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.6	0.7	0.8	0.7	1.1	0.9	1.1	1.3	1.6	2.0
5.3.1.2 Kaposi sarcoma	-	-	0.3	-	0.9	_	1.8	-	2.8	-
5.3.2 Unspecified soft tissue sarcoma	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.4	0.4
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	4.0	1.3	10.1	1.2	12.9	1.1	13.3	0.9	11.6	0.6
6.1 Germ cell and trophoblastic neoplasms of gonads	3.4	1.1	9.5	0.8	12.4	0.7	12.9	0.5	11.2	0.3
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.7	0.2	0.6	0.3	0.5	0.4	0.4	0.3	0.3	0.3
6.2.1 Intracranial sites	0.4	_	0.2	_	0.1	_	_	_	_	_
6.2.2 Other nongonadal sites	0.2	0.1	0.4	0.3	0.4	0.4	0.4	0.3	0.3	0.3

Rates are per 100,000.

a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3 definitions).

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

#### Table 32.4 - continued

# Age-Specific SEER Incidence<sup>a</sup>, by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup> All Races, 2002-2006

	Ages	15-19	Ages 20-24		20-24 Ages 25-29		Ages 30-34		Ages	35-39
Site	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	1.3	2.1	2.6	6.2	5.1	10.0	7.4	12.5	10.9	15.6
7.1 Melanoma	1.3	2.1	2.6	6.2	5.0	9.9	7.2	12.4	10.7	15.5
7.2 Skin carcinomas	-	-	-	-	-	0.1	0.2	-	0.2	0.2
8. CARCINOMAS (excluding skin)	2.0	4.7	4.1	15.0	9.1	35.5	17.6	71.8	35.8	126.9
8.1 Thyroid carcinoma	0.6	3.0	1.3	7.9	2.4	13.6	3.5	17.6	5.1	21.4
8.2 Other carcinoma of head and neck	0.5	0.4	0.6	0.8	1.1	1.2	2.1	1.8	4.0	2.7
8.2.1 Nasopharyngeal carcinoma	0.2	-	0.2	_	0.2	0.2	0.4	0.2	0.6	0.4
8.2.2 Other sites in lip, oral cavity and pharynx	0.2	0.3	0.3	0.6	0.8	0.9	1.3	1.4	2.8	1.9
8.2.3 Nasal cavity, middle ear, sinuses,	-	-	-	_	0.2	_	0.4	0.2	0.6	0.4
larynx, other ill-defined head/neck										
8.3 Carcinoma of trachea, bronchus, and lung	-	-	0.2	0.3	0.5	0.6	1.1	1.3	3.0	3.5
8.4 Carcinoma of breast	-	-	-	1.2	-	7.8	-	25.2	0.1	57.9
8.5 Carcinoma of genitourinary tract	0.3	0.6	0.6	3.0	1.4	9.0	3.2	18.9	7.7	28.5
8.5.1 Carcinoma of kidney	_	0.1	0.2	0.3	0.8	0.7	1.9	1.5	4.3	2.5
8.5.2 Carcinoma of bladder	0.1	_	0.3	0.2	0.5	0.3	1.1	0.4	2.2	0.9
8.5.3 Carcinoma of gonads	_	0.3	_	0.7	_	1.2	_	2.3	_	4.1
8.5.4 Carcinoma of cervix and uterus	_	_	_	1.7	_	6.6	_	14.1	_	19.6
8.5.5 Carcinoma of other and ill-defined sites,	_	_	_	_	_	0.2	0.3	0.5	1.2	1.3
genitourinary tract										
8.6 Carcinoma of gastrointestinal tract	0.5	0.5	1.3	1.5	3.2	2.8	6.9	6.2	14.5	11.6
8.6.1 Carcinoma of colon and rectum	0.2	0.3	0.7	1.0	2.0	1.8	4.4	4.3	9.1	7.7
8.6.2 Carcinoma of stomach	_	_	0.1	0.1	0.4	0.4	0.9	0.9	1.7	1.5
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.2	_	0.2	0.2	0.3	0.1	0.7	0.2	1.2	0.5
8.6.4 Carcinoma of pancreas	_	_	_	_	0.1	0.2	0.4	0.4	1.2	0.9
8.6.5 Carcinoma of other and ill-defined sites,			0.1	-	0.3	0.3	0.6	0.4	1.3	0.8
gastrointestinal tract	0 1		0 0	0 0	0 4	0 5	0 0	0 0	1 0	2 4
8.7 Carcinoma of other and ill-defined sites, NOS	0.1	-	0.2	0.2	0.4	0.5	0.7	0.8	1.3	1.4
8.7.1 Adrenocortical carcinoma	- 0 1	-	-	-	- 0 4	-		-	-	0.1
8.7.2 Carcinoma of other and ill-defined sites, NOS	0.1	-	0.2	0.2	0.4	0.4	0.7	0.8	1.2	1.2
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	0.2	0.5	0.3	0.5	0.4	0.8	0.9	1.3	1.6	2.2
9.1 Other pediatric and embryonal tumors, NOS	0.1	0.2	-	_	-	_	0.1	-	0.1	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	_	-	_	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	_	-	_	-	-	-	-
9.2 Other specified neoplasms, NOS	-	0.3	0.2	0.4	0.3	0.8	0.8	1.2	1.4	2.1
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	-	-	_	-	0.2	-	0.2	-	0.2
9.2.3 Myeloma, mast cell, miscellaneous	-	_	-	-	_	-	0.5	0.2	0.8	0.7
lymphoreticular neoplasms, NOS										
$9.2.4$ Other specified neoplasms, ${ m NOS}^{\rm c}$	-	0.2	-	0.2	0.2	0.5	0.2	0.8	0.5	1.2
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.2	0.2	0.2	0.3	0.3	0.5	0.5	0.8

Rates are per 100,000.

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-0 3.

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.5

Age-Specific SEER Incidence<sup>a</sup>, by Age Group and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>

White, 2002-2006

	Ages 15-19 Ages 20-24		Ages 25-29		Ages 30-34		Ages	35-39		
Site	Male	Female	Male	Female	Male	Female	Male	Female	Male	
All Sites Combined	24.5	21.2	36.2	38.5	48.7	66.4	64.5	108.7	91.1	169.5
1. LEUKEMIAS	4.3	2.3	3.2	2.1	2.7	2.0	3.3	2.6	4.2	3.1
1.1 Acute lymphoid leukemia	2.8	1.1	1.5	0.6	0.9	0.6	0.9	0.6	0.9	0.5
1.2 Acute myeloid leukemia	1.1	1.0	1.1	1.1	1.0	1.0	1.2	1.4	1.4	1.4
1.3 Chronic myeloid leukemia	0.2	-	0.4	0.3	0.5	0.3	0.7	0.4	1.1	0.7
1.4 Other and unspecified leukemias	0.2	-	0.2	-	0.3	-	0.5	0.2	0.9	0.5
2. LYMPHOMAS	5.5	4.4	7.4	6.8	8.0	7.7	9.6	8.0	12.5	8.3
2.1 Non-Hodgkin Lymphoma	2.4	1.2	2.8	1.8	3.6	2.8	5.4	3.7	8.9	5.3
2.2 Hodgkin Lymphoma	3.1	3.2	4.6	5.0	4.5	4.9	4.2	4.3	3.6	3.0
3. CNS, INTRACRANIAL, INTRASPINAL	2.5	2.0	2.5	2.5	3.5	2.9	4.0	2.9	4.5	3.7
3.1 Astrocytoma	1.5	1.0	1.3	1.5	1.7	1.4	2.0	1.6	2.6	1.8
3.1.1 Specified low-grade astrocytic tumors	0.9	0.7	0.4	0.6	0.3	0.4	0.4	0.3	0.4	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.4	_	0.6	0.5	0.7	0.6	1.2	0.8	1.6	1.1
3.1.3 Astrocytoma, NOS	0.3	_	0.4	0.4	0.6	0.4	0.4	0.4	0.6	0.4
3.2 Other glioma	0.4	0.4	0.6	0.6	1.3	0.9	1.4	0.9	1.4	1.3
3.3 Ependymoma	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.3	0.2	0.3
3.4 Medulloblastoma and other PNET	0.4	0.3	0.4	0.2	0.2	0.2	0.2	-	-	-
3.4.1 Medulloblastoma	0.2	-	0.2	0.2	-	-	-	_	_	_
3.4.2 Supratentorial PNET	0.2	0.2	-	-	_	_	_	_	_	_
3.5 Other specified intracranial and intraspinal neoplasms	-	-	_	_	_	_	_	_	_	_
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	_	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEPOLASMS	2.2	1.5	1.3	0.9	0.6	0.7	0.6	0.7	0.8	0.6
4.1 Osteosarcoma	1.1	0.7	0.6	0.4	_	0.3	_	0.2	0.2	_
4.2 Chondrosarcoma	0.2	_	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3
4.3 Ewing tumor	0.8	0.6	0.4	0.3	0.2	0.2	_	_	0.2	0.2
4.4 Other specified and unspecified bone tumors	-	-	-	-	-	-	-	-	0.2	-
5. SOFT TISSUE SARCOMAS	1.4	1.5	1.9	1.5	2.9	1.9	3.8	2.6	5.3	3.3
5.1 Fibromatous neoplasms	0.3	0.3	0.5	0.5	0.7	0.8	0.8	0.9	0.9	1.0
5.2 Rhabdomyosarcoma	0.4	0.3	0.2	-	_	-	_	_	_	_
5.3 Other specified soft tissue sarcoma	0.7	0.8	1.2	0.9	2.0	1.1	2.9	1.6	4.3	2.3
5.3.1 Specified soft tissue sarcoma	0.6	0.7	0.9	0.8	1.8	1.0	2.7	1.3	3.9	2.0
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.6	0.7	0.8	0.7	1.1	1.0	1.2	1.3	1.6	2.0
5.3.1.2 Kaposi sarcoma	-	-	-	-	0.7	_	1.4	-	2.4	-
5.3.2 Unspecified soft tissue sarcoma	0.2	-	0.2	_	0.2	-	0.3	0.3	0.4	0.3
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	4.6	1.3	12.0	1.1	15.5	1.1	16.0	0.9	13.7	0.5
6.1 Germ cell and trophoblastic neoplasms of gonads	4.0	1.1	11.3	0.8	14.9	0.7	15.5	0.5	13.3	0.2
6.2 Germ cell and trophoblastic neoplasms of	0.6	0.2	0.6	0.2	0.5	0.7	0.5	0.3	0.4	0.2
nongonadal sites	0.0	0.2	0.0	0.2	0.5	0.1	0.5	0.5	0.1	0.2
6.2.1 Intracranial sites	0.4	-	0.2	_	-	_	-	_	-	-
6.2.2 Other nongonadal sites	0.2	-	0.4	0.2	0.4	0.4	0.4	0.3	0.4	0.2

Rates are per 100,000.

a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3 definitions).

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

#### Table 32.5 - continued

# Age-Specific SEER Incidence $^a$ , by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults $^b$ White, 2002-2006

	Ages	15-19	5-19 Ages 20-24		Ages 25-29		Ages 30-34		Ages	35-39
Site	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	1.6	2.6	3.2	7.5	6.0	12.3	8.8	15.2	13.1	19.1
7.1 Melanoma	1.6	2.6	3.2	7.5	6.0	12.2	8.6	15.1	12.8	19.0
7.2 Skin carcinomas		-	-	-	-	-	0.2	-	0.2	0.1
8. CARCINOMAS (excluding skin)	2.0	5.0	4.2	15.4	8.8	36.6	17.4	74.0	35.3	128.2
8.1 Thyroid carcinoma	0.6	3.4	1.3	8.6	2.5	14.8	3.8	19.6	5.7	22.9
8.2 Other carcinoma of head and neck	0.5	0.3	0.5	0.7	1.0	1.0	1.8	1.6	3.8	2.4
8.2.1 Nasopharyngeal carcinoma	-	-	-	_	-	_	_	_	0.2	_
8.2.2 Other sites in lip, oral cavity and pharynx	0.3	0.2	0.4	0.6	0.7	0.8	1.4	1.3	2.9	1.8
8.2.3 Nasal cavity, middle ear, sinuses,	-	-	-	_	-	_	0.4	0.3	0.7	0.4
larynx, other ill-defined head/neck										
8.3 Carcinoma of trachea, bronchus, and lung	_	-	0.2	0.3	0.5	0.6	0.9	1.2	2.9	3.5
8.4 Carcinoma of breast	-	-	-	1.1	-	7.5	-	24.9	-	57.6
8.5 Carcinoma of genitourinary tract	0.2	0.7	0.6	2.9	1.5	9.4	3.4	19.9	7.9	29.6
8.5.1 Carcinoma of kidney	-	0.2	0.2	0.3	0.8	0.8	2.0	1.6	4.3	2.7
8.5.2 Carcinoma of bladder	_	_	0.3	0.2	0.5	0.3	1.2	0.4	2.4	1.0
8.5.3 Carcinoma of gonads	_	0.3	_	0.7	-	1.2	_	2.4	_	4.0
8.5.4 Carcinoma of cervix and uterus	_	_	_	1.6	-	6.9	_	15.0	_	20.5
8.5.5 Carcinoma of other and ill-defined sites,	_	_	_	_	_	_	0.2	0.5	1.1	1.4
genitourinary tract										
8.6 Carcinoma of gastrointestinal tract	0.5	0.5	1.3	1.5	3.0	2.8	6.6	6.0	13.7	10.9
8.6.1 Carcinoma of colon and rectum	0.2	0.3	0.8	1.1	2.1	1.9	4.4	4.1	9.0	7.5
8.6.2 Carcinoma of stomach	_	_	0.2	_	0.4	0.3	0.9	0.8	1.5	1.3
8.6.3 Carcinoma of liver and intrahepatic bile ducts	_	_	0.2	0.2	0.2	_	0.4	0.2	0.6	0.4
8.6.4 Carcinoma of pancreas	_	_	_	_	_	0.2	0.4	0.4	1.1	1.0
8.6.5 Carcinoma of other and ill-defined sites,		-	-	-	0.3	0.3	0.6	0.4	1.4	0.7
gastrointestinal tract										
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	-	0.2	0.3	0.4	0.7	0.7	1.2	1.4
8.7.1 Adrenocortical carcinoma	-	-	-	_	-	_	-	-	-	0.2
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	-	0.2	0.3	0.4	0.6	0.6	1.2	1.2
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	0.2	0.5	0.3	0.4	0.3	0.8	0.9	1.3	1.3	1.9
9.1 Other pediatric and embryonal tumors, NOS	_	0.2	-	-	_	-	-	_	-	-
9.1.1 Wilms tumor	-	-	-	-	_	-	_	-	-	_
9.1.2 Neuroblastoma	-	-	-	-	_	-	_	-	-	_
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	_	-	_	-	-	_
9.2 Other specified neoplasms, NOS	-	0.3	0.2	0.4	0.3	0.7	0.8	1.2	1.2	1.9
9.2.1 Paraganglioma and glomus tumors	-	-	-	_	-	_	_	_	-	_
9.2.2 Other specified gonadal tumors	_	-	-	-	-	0.2	-	0.2	-	0.2
9.2.3 Myeloma, mast cell, miscellaneous	_	_	_	_	-	_	0.5	0.2	0.7	0.5
lymphoreticular neoplasms, NOS										
9.2.4 Other specified neoplasms, NOS°	-	0.2	-	0.2	0.2	0.5	0.2	0.7	0.5	1.1
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.2	0.2	0.3	0.2	0.2	0.5	0.5	0.8

Rates are per 100,000.

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults.

Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3 definitions).

Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-0 3.

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Age-Specific SEER Incidence<sup>a</sup>, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>
Black, 2002-2006

	Ages 15-19 Ages 20-24 Ages 25-29		s 15-19 Ages 20-24 Ages 25-29 Ages 30-34		20-24 <u>Ages</u>		20-24 Ages 25-29		Ages 30-34 Ages 35-39		35-39
Site	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	
All Sites Combined	14.1	13.9	19.2	25.9	32.3	46.2	48.3	89.4	81.2	148.4	
1. LEUKEMIAS	2.0	1.9	2.4	2.0	2.7	1.3	3.5	2.7	4.2	2.3	
1.1 Acute lymphoid leukemia	-	-	1.1	_	-	-	-	-	-	-	
1.2 Acute myeloid leukemia	-	-	_	1.0	-	_	1.7	1.1	1.7	1.1	
1.3 Chronic myeloid leukemia	-	-	-	-	-	-	-	1.1	1.3	-	
1.4 Other and unspecified leukemias	-	-	-	-	-	-	-	-	-	-	
2. LYMPHOMAS	4.5	4.1	5.6	5.5	9.3	6.9	11.4	9.1	15.7	10.0	
2.1 Non-Hodgkin Lymphoma	2.4	1.6	3.0	2.4	5.4	2.4	7.6	5.4	11.9	7.2	
2.2 Hodgkin Lymphoma	2.1	2.5	2.6	3.1	3.9	4.5	3.8	3.7	3.8	2.9	
3. CNS, INTRACRANIAL, INTRASPINAL	1.3	1.2	1.6	1.0	1.4	1.5	1.6	2.1	2.2	1.6	
3.1 Astrocytoma	-	-	1.2	_	-	-	-	-	1.3	-	
3.1.1 Specified low-grade astrocytic tumors	-		-	-	-		-	-	-	-	
3.1.2 Glioblastoma and anaplastic astrocytoma	-	-	-	-	-	-	-	-	-	-	
3.1.3 Astrocytoma, NOS	-	-	-	-	-	-	-	-	-	-	
3.2 Other glioma	-	-	-	-	-		-	-	-	-	
3.3 Ependymoma	-	-	-	-	-	-	-	-	-	-	
3.4 Medulloblastoma and other PNET	-	_	_	-	-	_	-	-	-	-	
3.4.1 Medulloblastoma	-	-	-	-	-	-	-	-	-	-	
3.4.2 Supratentorial PNET 3.5 Other specified intracranial and intraspinal neoplasms	_	-	_	_	-	-	-	_	-	-	
3.6 Unspecified intracranial and intraspinal neoplasms	_	_	_	_	_	_	_	_	_	_	
4. OSSEOUS & CHONDROMATOUS NEPOLASMS	1.7	-	0.9	-	-	-	-	-	-	-	
4.1 Osteosarcoma	1.6	-	-	-	-	-	-	-	-	-	
4.2 Chondrosarcoma	-	_	-	-	-		-	-	-	-	
4.3 Ewing tumor	-	-	_	-	-	_	-	_	-	-	
4.4 Other specified and unspecified bone tumors	-	-	-	_	_	_	-	-	-	-	
5. SOFT TISSUE SARCOMAS	1.3	1.9	2.8	2.9	5.8	3.2	8.6	3.7	12.5	5.6	
5.1 Fibromatous neoplasms	-	-	-	_	-	1.8	1.6	1.6	1.5	1.6	
5.2 Rhabdomyosarcoma	-	-	-	-	-	_	-	-	<del>-</del>	-	
5.3 Other specified soft tissue sarcoma	-		2.2	1.8	4.7	1.4	6.7	2.0	10.8	3.8	
5.3.1 Specified soft tissue sarcoma	_	_	2.0	1.3	4.2	-	6.0	1.8	10.1	2.9	
5.3.1.1 Specified (excluding Kaposi sarcoma) 5.3.1.2 Kaposi sarcoma	_	-	- 1.3	1.1	1.1 3.2	_	- 5.0	1.7	2.4 7.7	2.7	
5.3.1.2 Raposi sarcoma 5.3.2 Unspecified soft tissue sarcoma	_	_	1.3	_	3.∠	_	5.0	_	-	0.9	
5.5.2 Unspecified soft cissue sarcoma	-	_	_	_	_	_	_	_	_	0.9	
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	1.0	1.2	1.8	1.0	2.5		3.5	-	2.8	-	
6.1 Germ cell and trophoblastic neoplasms of gonads	-	-	1.6	_	1.9	_	3.3	-	2.7	-	
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	-	-	-	-,	-		-		-		
6.2.1 Intracranial sites	-	-	-	_	-	_	-	_	-	_	
6.2.2 Other nongonadal sites	-	-	-	_	-	-	-	-	-	-	

Rates are per 100,000.

a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3 definitions).

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

#### Table 32.6 - continued

# Age-Specific SEER Incidence $^a$ , by Age Group and Sex By Adapted Classification Scheme for Tumors of Adolescents and Young Adults $^b$ Black, 2002-2006

	Ages 15-19 Ages 20-24		Ages 25-29		Ages 30-34		Ages	35-39		
Site	Male	Female	Male	Female	Male			Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	-	-	_	-	_	_	-	-	1.1	0.9
7.1 Melanoma			-	-	-	-	-	-	-	
7.2 Skin carcinomas	-	-	-	-	-	-	-	-	-	-
8. CARCINOMAS (excluding skin)	2.0	2.1	3.6	11.4	8.6	30.0	16.7	66.7	37.9	120.9
8.1 Thyroid carcinoma	-	-	-	3.5	1.2	6.3	1.4	7.7	2.2	11.2
8.2 Other carcinoma of head and neck			-	-	1.4	_	1.9	1.7	3.8	2.7
8.2.1 Nasopharyngeal carcinoma			-	-	-	_	-	-	-	
8.2.2 Other sites in lip, oral cavity and pharynx	_	-	-	-	-	-	-	1.4	2.4	1.9
8.2.3 Nasal cavity, middle ear, sinuses,			-	-	-	_	-	-	-	
larynx, other ill-defined head/neck										
8.3 Carcinoma of trachea, bronchus, and lung	_	-	-	-	-	-	1.5	1.3	3.5	3.9
8.4 Carcinoma of breast			-	1.8	-	10.6	-	29.9	-	63.5
8.5 Carcinoma of genitourinary tract			-	3.3	1.7	9.0	3.2	17.2	9.1	24.6
8.5.1 Carcinoma of kidney			-	-	1.2	-	2.0	1.9	5.2	3.0
8.5.2 Carcinoma of bladder	-	-	_	_	-	_	_	_	1.6	_
8.5.3 Carcinoma of gonads	-	-	_	_	-	_	_	2.0	_	3.5
8.5.4 Carcinoma of cervix and uterus	-	-	_	2.5	-	6.6	_	12.1	_	16.0
8.5.5 Carcinoma of other and ill-defined sites,	_	_	-	_	_	_	_	1.0	2.2	1.6
genitourinary tract										
8.6 Carcinoma of gastrointestinal tract	_	_	1.2	1.3	2.6	2.1	7.6	7.4	17.3	13.5
8.6.1 Carcinoma of colon and rectum	_	_	-	_	1.3	1.2	4.9	5.3	11.3	8.5
8.6.2 Carcinoma of stomach	_	_	-	_	_	_	_	_	1.9	1.7
8.6.3 Carcinoma of liver and intrahepatic bile ducts	_	_	-	_	_	_	1.2	_	1.5	1.0
8.6.4 Carcinoma of pancreas	_	_	-	_	_	_	_	_	1.3	_
8.6.5 Carcinoma of other and ill-defined sites,	-	-	-	-	-	-	-	-	1.4	1.5
gastrointestinal tract										
8.7 Carcinoma of other and ill-defined sites, NOS	-	-	-	-	-	-	-	1.6	1.7	1.5
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	-
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	-	-	-	-	-	1.6	1.7	1.4
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	-	-	_	_	-	1.0	1.2	2.2	3.5	4.7
9.1 Other pediatric and embryonal tumors, NOS	-	-	_	_	-	_	_	_	_	_
9.1.1 Wilms tumor	-	-	_	_	-	_	_	_	_	_
9.1.2 Neuroblastoma	-	-	_	_	-	_	_	_	_	_
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	_	_	-	_	_	_	_	_
9.2 Other specified neoplasms, NOS	_	_	-	_	_	1.0	1.1	2.2	3.3	4.4
9.2.1 Paraganglioma and glomus tumors	-	-	_	_	-	_	_	_	_	_
9.2.2 Other specified gonadal tumors	-	-	_	_	-	_	_	_	_	_
9.2.3 Myeloma, mast cell, miscellaneous	_	_	_	_	_	_	_	_	2.1	2.0
lymphoreticular neoplasms, NOS										
9.2.4 Other specified neoplasms, NOSc	-	-	-	-	-	-	-	1.2	1.0	2.0
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	-	-	-	-	-	-	-	1.2

Rates are per 100,000.

- SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
- Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults.
- Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3 definitions).

  Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-0 3.
- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.7

Age-Adjusted SEER Incidence<sup>a</sup>, by Year and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>

All Races, Ages 15-19

	1	L975-200	6	1997-2006			
Both Sexes	No.	Rate	AAPC°	No.	Rate	AAPC°	
All Sites Combined	11,591	20.0	0.3	3,920	20.8	-0.2	
1. Leukemias	1,390	2.4	0.9*	503	2.7	0.9*	
2. Lymphomas	2,900	5.0	-0.2	890	4.7	-1.2*	
3. CNS, intracranial, intraspinal	1,137	2.0	0.4	369	2.0	0.4	
4. Osseous & chondromatous nepolasms	910	1.6	0.7	313	1.7	0.7	
5. Soft tissue sarcomas	868	1.5	0.6	311	1.7	0.6	
6. Germ cell and trophoblastic neoplasms	1,398	2.4	0.9*	484	2.6	0.9*	
7. Melanoma and skin carcinomas	880	1.5	1.4*	322	1.7	1.4*	
8. Carcinomas (excluding skin)	1,880	3.2	0.7*	669	3.6	0.7*	
9. Miscellaneous specified neoplasms, NOS	177	0.3	-0.1	51	0.3	-0.1	
10. Unspecified malignant neoplasms	51	0.1	-	-	-	-	
	1	L975-200	6	1	L997-200	6	
Males	No.	Rate	AAPC°	No.	Rate	AAPC°	
All Sites Combined	6,110	20.7	0.7*	2,112	21.9	0.7*	
1. Leukemias	847	2.9	0.7*	302	3.1	0.7*	
2. Lymphomas	1,547	5.2	-0.1	486	5.0	-0.1	
3. CNS, intracranial, intraspinal	665	2.3	0.4	219	2.3	0.4	
4. Osseous & chondromatous nepolasms	587	2.0	0.8	201	2.1	0.8	
5. Soft tissue sarcomas	457	1.5	0.5	163	1.7	0.5	
6. Germ cell and trophoblastic neoplasms	1,011	3.4	1.3*	371	3.8	1.3*	
7. Melanoma and skin carcinomas	347	1.2	1.9*	133	1.4	1.9*	
8. Carcinomas (excluding skin)	549	1.9	1.4*	216	2.2	1.4*	
9. Miscellaneous specified neoplasms, NOS	78	0.3	-	19	0.2	-	
10. Unspecified malignant neoplasms	22	0.1	-	-	-	-	
	1	L975-200	6	1	L997-200	6	
Females	No.	Rate	AAPC	No.	Rate	AAPC	
All Sites Combined	5,481	19.3	0.3*	1,808	19.7	0.3*	
1. Leukemias	543	1.9	1.2*	201	2.2	1.2*	
2. Lymphomas	1,353	4.8	-0.4	404	4.4	-0.4	
3. CNS, intracranial, intraspinal	472	1.7	0.2	150	1.6	0.2	
4. Osseous & chondromatous nepolasms	323	1.1	0.4	112	1.2	0.4	
5. Soft tissue sarcomas	411	1.4	0.9	148	1.6	0.9	
6. Germ cell and trophoblastic neoplasms	387	1.4	-0.2	113	1.2	-0.2	
7. Melanoma and skin carcinomas	533	1.9	1.1*	189	2.1	1.1*	
8. Carcinomas (excluding skin)	1,331	4.7	0.4	453	4.9	0.4	
9. Miscellaneous specified neoplasms, NOS	99	0.3	-	32	0.3	_	
10. Unspecified malignant neoplasms	29	0.1	-	_	-	-	

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults.

Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2006.

<sup>-</sup> Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

Table 32.8

Age-Adjusted SEER Incidence<sup>a</sup>, by Year and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>

All Races, Ages 20-24

		L975-200	6	1	1997-2006				
Both Sexes	No.	Rate	AAPC°	No.	Rate	AAPC°			
All Sites Combined	10 013	22.4	0 0+	6 675	26.4	0 0+			
1. Leukemias	19,913	33.4	0.8*	6,675 451	36.4 2.5	0.8* 1.0*			
	1,288	7.1	1.0* 0.9*		7.4	-0.1			
2. Lymphomas	4,233			1,361					
3. CNS, intracranial, intraspinal 4. Osseous & chondromatous nepolasms	1,318 521	2.2	0.8* 1.3*	431 184	2.4	0.8* 1.3*			
5. Soft tissue sarcomas	1,250	2.1	0.8	362	2.0	-2.4*			
		5.2			5.7	0.8*			
6. Germ cell and trophoblastic neoplasms 7. Melanoma and skin carcinomas	3,088	4.2	0.8*	1,053 943		1.5*			
	2,528		1.5*		5.1				
8. Carcinomas (excluding skin)	5,367	9.0	0.2	1,776	9.7	1.4*			
9. Miscellaneous specified neoplasms, NOS	197	0.3	1.6*	73	0.4	1.6*			
10. Unspecified malignant neoplasms	123	0.2	0.6	41	0.2	0.6			
	-	L975-200	6	1	L997-200	6			
Males	No.	Rate	AAPC°	No.	Rate	AAPC°			
All Sites Combined	9,841	32.5	0.6*	3,187	33.8	0.1			
1. Leukemias	751	2.5	0.9*	256	2.7	0.9*			
2. Lymphomas	2,269	7.5	0.4	714	7.6	0.4			
3. CNS, intracranial, intraspinal	752	2.5	0.3	227	2.4	0.3			
4. Osseous & chondromatous nepolasms	306	1.0	0.8	104	1.1	0.8			
5. Soft tissue sarcomas	750	2.5	0.6	198	2.1	-3.8*			
6. Germ cell and trophoblastic neoplasms	2,760	9.1	0.8*	953	10.1	0.8*			
7. Melanoma and skin carcinomas	881	2.9	0.5	301	3.2	0.5			
8. Carcinomas (excluding skin)	1,246	4.1	-0.1	394	4.2	-0.1			
9. Miscellaneous specified neoplasms, NOS	79	0.3	-	27	0.3	-			
10. Unspecified malignant neoplasms	47	0.2	-	-	-	-			
		L975-200	6	-	L997-200	6			
Females	No.	Rate	AAPC°	No.	Rate	AAPC°			
All Sites Combined	10,072	34.3	0.9*	3,488	39.1	1.5*			
1. Leukemias	537	1.8	0.1	195	2.2	-0.4			
2. Lymphomas	1,964	6.7	1.8	647	7.3	3.7*			
3. CNS, intracranial, intraspinal	566	1.9	1.6*	204	2.3	1.6*			
4. Osseous & chondromatous nepolasms	215	0.7	1.7*	80	0.9	1.7*			
5. Soft tissue sarcomas	500	1.7	-0.8	164	1.8	-6.9			
6. Germ cell and trophoblastic neoplasms	328	1.1	0.0	100	1.1	0.0			
7. Melanoma and skin carcinomas	1,647	5.6	2.1*	642	7.2	2.1*			
8. Carcinomas (excluding skin)	4,121	14.0	0.4	1,382	15.5	1.6*			
9. Miscellaneous specified neoplasms, NOS	118	0.4	1.9*	46	0.5	1.9*			
10. Unspecified malignant neoplasms	76	0.3	-	28	0.3	-			

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults.

Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2006.

<sup>-</sup> Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

Table 32.9

Age-Adjusted SEER Incidence<sup>a</sup>, by Year and Sex

By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>

All Races, Ages 25-29

		L975-200	6		6	
Both Sexes	No.	Rate	AAPC	No.	Rate	AAPC
all other combined	22 000	E 4 1	0 7+	10 760	F.C. 0	1 14
All Sites Combined	33,988	54.1	0.7*	10,769	56.9	1.1*
1. Leukemias	1,436	2.3	0.3	472	2.5	0.3
2. Lymphomas	5,168	8.2	0.6	1,545	8.2	-0.6
3. CNS, intracranial, intraspinal	1,779	2.8	1.2*	609	3.2	1.2*
4. Osseous & chondromatous nepolasms	406	0.6	0.7	130	0.7	0.7
5. Soft tissue sarcomas	2,715	4.3	1.4	544	2.9	-1.6
6. Germ cell and trophoblastic neoplasms	4,290	6.8	1.6*	1,376	7.3	2.3
7. Melanoma and skin carcinomas	4,658	7.4	1.5*	1,638	8.7	3.3*
8. Carcinomas (excluding skin)	13,062	20.8	0.2	4,287	22.6	1.2*
9. Miscellaneous specified neoplasms, NOS	305	0.5	1.5*	120	0.6	1.5*
10. Unspecified malignant neoplasms	169	0.3	-	48	0.3	-
	-	L975-200	6	<u>-</u>	L997-200	6
Males	No.	Rate	AAPC	No.	Rate	AAPC°
All Sites Combined	15,470	49.0	0.8*	4,701	48.9	0.4
1. Leukemias	839	2.7	-0.3	269	2.8	1.3*
2. Lymphomas	2,952	9.3	0.0	831	8.6	-3.8*
3. CNS, intracranial, intraspinal	960	3.0	0.9*	318	3.3	0.9*
4. Osseous & chondromatous nepolasms	236	0.7	-0.3	64	0.7	-0.3
5. Soft tissue sarcomas	2,024	6.4	1.9	359	3.7	-1.3
6. Germ cell and trophoblastic neoplasms	3,948	12.5	1.7*	1,290	13.4	2.2
7. Melanoma and skin carcinomas	1,713	5.4	0.4	557	5.8	0.4
8. Carcinomas (excluding skin)	2,614	8.3	0.0	940	9.8	1.8*
9. Miscellaneous specified neoplasms, NOS	111	0.4	_	50	0.5	_
10. Unspecified malignant neoplasms	73	0.2	-	23	0.2	-
		1075 200	_		1007 000	_
Females	No.	1975-200 Rate	AAPC <sup>c</sup>	No.	1997-200 Rate	AAPC <sup>c</sup>
1 CMATCS	110.	nace	AALC	140.	Race	AHIC
All Sites Combined	18,518	59.4	0.6*	6,068	65.1	1.1*
1. Leukemias	597	1.9	0.9	203	2.2	0.9
2. Lymphomas	2,216	7.1	1.1*	714	7.7	1.1*
3. CNS, intracranial, intraspinal	819	2.6	1.5*	291	3.1	1.5*
4. Osseous & chondromatous nepolasms	170	0.5	1.7	66	0.7	1.7
5. Soft tissue sarcomas	691	2.2	0.5	185	2.0	-2.9*
6. Germ cell and trophoblastic neoplasms	342	1.1	-1.1	86	0.9	-1.1
7. Melanoma and skin carcinomas	2,945	9.4	1.9*	1,081	11.6	1.9*
8. Carcinomas (excluding skin)	10,448	33.5	0.2	3,347	35.9	1.0*
9. Miscellaneous specified neoplasms, NOS	194	0.6	0.9	70	0.8	0.9
10. Unspecified malignant neoplasms	96	0.3	-	25	0.3	-
To. onspectited marryname neoptasms	90	0.3	_	25	0.3	_

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults.

Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3

definitions).

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by
Joinpoint over the time range of 1975-2006.

<sup>-</sup> Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

Table 32.10  $\hbox{Age-Adjusted SEER Incidence}^a, \ by \ Year \ and \ Sex \\ \hbox{By Adapted Classification Scheme for Tumors of Adolescents and Young Adults}^b \\ \hbox{All Races, Ages } 30-34$ 

		1975-200		1997-2006			
Both Sexes	No.	Rate	AAPC°	No.	Rate	AAPC°	
All Sites Combined	52,777	83.2	0.5	17,297	84.6	-0.3	
1. Leukemias	1,770	2.8	0.6	615	3.0	0.6	
2. Lymphomas	5,856	9.2	1.6*	1,908	9.3	-1.7	
3. CNS, intracranial, intraspinal	2,095	3.3	0.2	682	3.3	0.2	
4. Osseous & chondromatous nepolasms	403	0.6	1.0	144	0.7	1.0	
5. Soft tissue sarcomas	4,660	7.4	0.9	826	4.0	-7.1*	
6. Germ cell and trophoblastic neoplasms	4,349	6.9	1.7*	1,545	7.6	-0.2	
7. Melanoma and skin carcinomas	6,714	10.6	1.6*	2,330	11.4	1.5	
8. Carcinomas (excluding skin)	26,153	41.3	0.3	8,945	43.7	1.7*	
9. Miscellaneous specified neoplasms, NOS	528	0.8	1.5*	217	1.1	1.5*	
10. Unspecified malignant neoplasms	248	0.4	0.9	84	0.4	0.9	
	-	1975-200	6	1	L997-200	6	
Males	No.	Rate	AAPC	No.	Rate	AAPC°	
All Sites Combined	22,263	70.2	0.7	6,706	64.9	-0.9	
1. Leukemias	1,024	3.2	0.8*	364	3.5	0.8*	
2. Lymphomas	3,670	11.6	0.7	1,097	10.6	-3.5*	
3. CNS, intracranial, intraspinal	1,220	3.8	0.1	390	3.8	0.1	
4. Osseous & chondromatous nepolasms	224	0.7	0.9	79	0.8	0.9	
5. Soft tissue sarcomas	3,833	12.1	1.2	564	5.5	-10.1*	
6. Germ cell and trophoblastic neoplasms	4,067	12.8	1.8*	1,460	14.1	0.0	
7. Melanoma and skin carcinomas	2,701	8.5	-0.2	859	8.3	-0.2	
8. Carcinomas (excluding skin)	5,233	16.5	0.5	1,771	17.1	3.0*	
9. Miscellaneous specified neoplasms, NOS	200	0.6	1.8*	88	0.9	1.8*	
10. Unspecified malignant neoplasms	91	0.3	-	34	0.3	-	
		1075 200	c		1007 200	c	
Females	No.	1975-200 Rate	AAPC°	No.	1997-200 Rate	AAPC°	
remares	110.	nace	AAIC	110.	Race	AALC	
All Sites Combined	30,514	96.4	0.6*	10,591	104.6	1.4*	
1. Leukemias	746	2.4	0.2	251	2.5	0.2	
2. Lymphomas	2,186	6.9	1.6*	811	8.0	1.6*	
3. CNS, intracranial, intraspinal	875	2.8	0.4	292	2.9	0.4	
4. Osseous & chondromatous nepolasms	179	0.6	_	65	0.6		
5. Soft tissue sarcomas	827	2.6	0.0	262	2.6	0.0	
6. Germ cell and trophoblastic neoplasms	282	0.9	-0.4	85	0.8	-0.4	
7. Melanoma and skin carcinomas	4,013	12.7	2.4*	1,471	14.5	1.1*	
8. Carcinomas (excluding skin)	20,920	66.1	0.3	7,174	70.9	1.5*	
9. Miscellaneous specified neoplasms, NOS	328	1.0	1.4*	129	1.3	1.4*	
10. Unspecified malignant neoplasms	157	0.5	-	50	0.5	-	
10. Onspectifica marranane neoptasms	137	0.5		50	0.5		

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults.

Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2006.

<sup>-</sup> Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

Table 32.11

Age-Adjusted SEER Incidence<sup>a</sup>, by Year and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults<sup>b</sup>
All Races, Ages 35-39

		L975-200	6		1997-200	06	
Both Sexes	No.	Rate	AAPC	No.	Rate	AAPC°	
All Sites Combined	77,441	130.2	0.4	27,889	129.3	0.0	
1. Leukemias	2,165	3.6	-0.2	785	3.6	-0.2	
2. Lymphomas	6,599	11.1	1.9*	2,402	11.1	-1.9*	
3. CNS, intracranial, intraspinal	2,355	4.0	-0.2	851	3.9	-0.2	
4. Osseous & chondromatous nepolasms	368	0.6	1.2*	140	0.6	1.2*	
5. Soft tissue sarcomas	5,430	9.1	1.5	1,133	5.3	-3.4	
6. Germ cell and trophoblastic neoplasms	3,441	5.8	2.0*	1,406	6.5	0.6	
7. Melanoma and skin carcinomas	8,362	14.1	1.7*	3,179	14.7	0.1	
8. Carcinomas (excluding skin)	47,367	79.7	0.2	17,477	81.0	1.0*	
9. Miscellaneous specified neoplasms, NOS	959	1.6	0.9*	384	1.8	0.9*	
10. Unspecified malignant neoplasms	395	0.7	-0.2	132	0.6	-0.2	
	<u>-</u>	L975-200	6	<u>-</u>	1997-200	6	
Males	No.	Rate	AAPC°	No.	Rate	AAPC°	
All Sites Combined	29,651	100.0	0.5	10,069	93.0	-0.9	
1. Leukemias	1,267	4.3	-0.2	462	4.3	-0.2	
2. Lymphomas	4,370	14.7	1.9*	1,476	13.6	-3.4*	
3. CNS, intracranial, intraspinal	1,366	4.6	-0.2	490	4.5	-0.2	
4. Osseous & chondromatous nepolasms	214	0.7	0.4	76	0.7	0.4	
5. Soft tissue sarcomas	4,350	14.7	2.9	772	7.1	-4.9*	
6. Germ cell and trophoblastic neoplasms	3,267	11.0	2.1*	1,353	12.5	0.5	
7. Melanoma and skin carcinomas	3,710	12.5	0.7	1,319	12.2	-1.1*	
8. Carcinomas (excluding skin)	10,548	35.6	-0.1	3,913	36.1	-0.1	
9. Miscellaneous specified neoplasms, NOS	394	1.3	0.6	159	1.5	0.6	
10. Unspecified malignant neoplasms	165	0.6	0.2	49	0.5	-4.6*	
		L975-200			1997-200		
<u>Females</u>	No.	Rate	AAPC	No.	Rate	AAPC	
All Sites Combined	47,790	160.3	0.6*	17,820	165.9	0.9*	
1. Leukemias	898	3.0	0.1	323	3.0	-1.2	
2. Lymphomas	2,229	7.5	1.6*	926	8.6	1.6*	
3. CNS, intracranial, intraspinal	989	3.3	-0.2	361	3.4	-0.2	
4. Osseous & chondromatous nepolasms	154	0.5	-	64	0.6	-	
5. Soft tissue sarcomas	1,080	3.6	-0.7	361	3.4	-0.7	
6. Germ cell and trophoblastic neoplasms	174	0.6	-0.8	53	0.5	-0.8	
7. Melanoma and skin carcinomas	4,652	15.6	2.3*	1,860	17.3	0.7	
8. Carcinomas (excluding skin)	36,819	123.5	0.3	13,564	126.3	1.1*	
9. Miscellaneous specified neoplasms, NOS	565	1.9	1.1*	225	2.1	1.1*	
10. Unspecified malignant neoplasms	230	0.8	-0.2	83	0.8	-0.2	

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults.

Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-0-3

definitions).
The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2006.

<sup>-</sup> Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

			Inciden	ce_				Mortali	<u>ty</u>	
* 1	All	TT	D1 1	a D T C	· d	All	777	D1 1	3.D.T.C	· d
Males	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	22.4	24.5	14.1	16.6	21.8					
T autromá a	2 0	4 2	2.0	2.7	5.7					
Leukemia	3.9	4.3								
Lymphoma	5.2	5.5	4.5	3.6	4.2					
Hodgkin Lymphoma	2.9	3.1	2.1	2.1	2.2					
Non-Hodgkin Lymphoma	2.3	2.4	2.4	1.5	2.0					
Brain and Other Nervous System	2.4	2.6	1.6	1.6	1.9					
Bones and Joints	1.9	1.9	1.8	1.8	1.8					
Soft Tissue including Heart	1.2	1.2	0.9	1.3	1.2					
Skin excluding Basal and Squamous	1.4	1.8	-	_	-					
Respiratory System	0.5	0.5	-	-	0.6					
Male Genital System	3.5	4.2	-	2.0	4.0					
Digestive System	0.6	0.6	-	-	0.5					
			Inciden	ce_				Mortali	Ly_	

			Inciden	<u>ce</u>		<u>Mortality</u>				
	All					All				
Females	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	19.9	21.2	13.9	15.2	17.0					
Leukemia	2.2	2.3	1.9	1.8	3.0					
Lymphoma	4.3	4.4	4.1	3.2	3.0					
Hodgkin Lymphoma	3.0	3.2	2.5	1.4	2.0					
Non-Hodgkin Lymphoma	1.3	1.2	1.6	1.8	1.0					
Brain and Other Nervous System	1.9	2.0	1.3	1.6	1.6					
Bones and Joints	1.2	1.3	_	-	1.3					
Soft Tissue including Heart	1.2	1.1	1.1	1.4	1.2					
Skin excluding Basal and Squamous	2.3	2.7	_	_	_					
Respiratory System	0.2	0.3	_	-	-					
Breast	0.2	0.2	_	_	_					
Female Genital System	1.8	1.8	1.6	1.9	2.4					
Digestive System	0.6	0.6	_	-	0.8					

Rates are per 100,000.

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

b US Mortality Files, National Center for Health Statistics, CDC.

c Asian/Pacific Islander

d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

			119	,00 20 21	•					
				Mortali	ty					
	All					All		-		
Males	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	32.8	36.2	19.2	20.1	29.2					
Leukemia	3.0	3.2	2.4	2.4	4.2					
Lymphoma	7.1	7.4	5.6	6.1	4.7					
Hodgkin Lymphoma	4.2	4.6	2.6	3.1	2.4					
Non-Hodgkin Lymphoma	2.9	2.8	3.0	3.0	2.2					
Brain and Other Nervous System	2.3	2.5	1.7	-	2.0					
Bones and Joints	1.1	1.2	0.9	-	1.2					
Soft Tissue including Heart	1.2	1.3	1.1	-	0.9					
Skin excluding Basal and Squamous	2.8	3.4	-	-	0.7					
Respiratory System	0.7	0.8	-	-	0.8					
Male Genital System	9.7	11.6	1.8	3.6	10.8					
Digestive System	1.4	1.5	1.2	-	1.7					
			Inciden	ce				Mortali	ty_	
	All					All				
Females	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	36.2	38.5	25.9	26.5	26.6					
Leukemia	2.0	2.1	2.0	1.3	2.3					
Lymphoma	6.5	6.8	5.5	4.7	3.8					

	ATT.					ATT.				
Females	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	36.2	38.5	25.9	26.5	26.6					
- 1	0.0	0 1	0 0	1 2	0 2					
Leukemia	2.0	2.1	2.0	1.3	2.3					
Lymphoma	6.5	6.8	5.5	4.7	3.8					
Hodgkin Lymphoma	4.6	5.0	3.1	3.2	2.4					
Non-Hodgkin Lymphoma	1.9	1.8	2.4	1.5	1.4					
Brain and Other Nervous System	2.3	2.6	1.1	1.4	1.7					
Bones and Joints	0.7	0.8	-	-	0.8					
Soft Tissue including Heart	1.1	1.0	2.0	_	1.0					
Skin excluding Basal and Squamous	6.4	7.7	-	-	1.7					
Respiratory System	0.5	0.5	-	-	0.6					
Breast	1.4	1.3	1.9	1.3	1.2					
Female Genital System	4.0	3.8	4.3	4.6	3.9					
Digestive System	1.7	1.7	1.4	1.4	1.4					

Rates are per 100,000.

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

b US Mortality Files, National Center for Health Statistics, CDC.

c Asian/Pacific Islander

d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.14

SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rate Comparison by Race/Ethnicity, 2002-2006

Ages 25-29

			Ag	CB 25 25						
			Inciden	ce_				Mortali	ty_	
	All					All				
Males	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	45.1	48.7	32.3	26.1	32.4					
Leukemia	2.7	2.7	2.7	2.5	3.3					
Lymphoma	7.8	8.0	9.3	3.9	4.7					
Hodgkin Lymphoma	4.1	4.5	3.9	1.2	1.9					
Non-Hodgkin Lymphoma	3.7	3.6	5.4	2.7	2.9					
Brain and Other Nervous System	3.1	3.5	1.4	2.0	2.1					
Bones and Joints	0.5	0.5	-	-	0.5					
Soft Tissue including Heart	1.6	1.6	2.1	-	1.3					
Skin excluding Basal and Squamous	5.5	6.4	-	1.2	0.9					
Respiratory System	1.1	1.1	1.5	-	1.0					
Male Genital System	12.7	15.2	2.2	3.2	10.8					
Digestive System	3.5	3.4	2.9	4.9	3.0					
			<u>Inciden</u>	ce_				Mortali	ty_	
	All					All				
Females	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Maliament Concern	62.2	66 1	16 2	12 2	16 0					

			<u>Inciden</u>	<u>ce</u>		<u>Mortality</u>				
	All					All				
Females	Races	White	Black	API <sup>c</sup>	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	62.2	66.4	46.2	42.2	46.8					
Leukemia	1.9	2.0	1.3	2.0	2.1					
Lymphoma	7.3	7.7	6.9	4.3	4.9					
Hodgkin Lymphoma	4.6	4.9	4.5	2.5	2.7					
Non-Hodgkin Lymphoma	2.7	2.8	2.4	1.8	2.2					
Brain and Other Nervous System	2.5	2.9	1.6	1.3	1.7					
Bones and Joints	0.6	0.6	-	-	-					
Soft Tissue including Heart	1.3	1.2	1.8	-	1.2					
Skin excluding Basal and Squamous	10.4	12.6	1.2	-	2.8					
Respiratory System	0.7	0.8	-	-	0.6					
Breast	8.1	7.8	11.2	6.5	7.0					
Female Genital System	9.6	10.0	9.4	6.2	9.8					
Digestive System	3.1	3.1	2.3	3.1	2.8					

Rates are per 100,000.

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

b US Mortality Files, National Center for Health Statistics, CDC.

Asian/Pacific Islander

Hispanic is not mutually exclusive from Whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.15

SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rate Comparison by Race/Ethnicity, 2002-2006

Ages 30-34

			Ag	es 30-34							
			Inciden	ce_			Mortality_				
	All					All					
Males	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>	
All Malignant Cancers	60.5	64.5	48.3	36.4	42.3						
Leukemia	3.3	3.3	3.6	3.0	3.1						
Lymphoma	9.3	9.6	11.4	5.1	6.4						
Hodgkin Lymphoma	3.8	4.2	3.8	1.6	2.3						
Non-Hodgkin Lymphoma	5.5	5.4	7.6	3.5	4.1						
Brain and Other Nervous System	3.6	4.0	1.6	2.3	2.4						
Bones and Joints	0.5	0.6	_	-	0.4						
Soft Tissue including Heart	1.8	1.7	2.6	1.1	1.6						
Skin excluding Basal and Squamous	7.8	9.1	1.6	1.0	1.5						
Respiratory System	1.9	1.8	2.0	2.5	1.6						
Male Genital System	13.2	15.8	3.7	3.7	10.3						
Digestive System	7.4	7.1	8.2	7.9	6.5						
			Inciden	ce				Mortalit	.y		
	All					All		-			
Females	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>	
All Malignant Cancers	103.5	108.7	89.4	75.2	81.3						

	<u>Incidence</u>				<u>Mortality</u>					
	All					All				
Females	Races	White	Black	APIc	Hispanic <sup>d</sup>	Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	103.5	108.7	89.4	75.2	81.3					
Leukemia	2.6	2.6	2.7	2.4	3.2					
Lymphoma	7.8	8.0	9.1	4.6	5.4					
Hodgkin Lymphoma	3.8	4.3	3.7	1.4	2.2					
Non-Hodgkin Lymphoma	4.0	3.7	5.4	3.2	3.2					
Brain and Other Nervous System	2.8	3.0	2.1	2.1	2.0					
Bones and Joints	0.6	0.6	-	-	0.8					
Soft Tissue including Heart	1.5	1.6	1.9	-	1.6					
Skin excluding Basal and Squamous	12.9	15.5	1.9	2.0	3.8					
Respiratory System	1.6	1.7	1.4	1.7	1.0					
Breast	25.6	25.3	30.4	22.5	19.9					
Female Genital System	18.7	19.6	17.3	13.2	18.9					
Digestive System	6.6	6.4	8.0	6.4	6.5					

Rates are per 100,000.

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

US Mortality Files, National Center for Health Statistics, CDC.

Asian/Pacific Islander

d Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 32.16

SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rate Comparison by Race/Ethnicity, 2002-2006

Ages 35-39

			Inciden	ce				Mortali	<u>zy</u>	
Males	All Races	White	Black	APIc	Hispanic <sup>d</sup>	All Races	White	Black	APIc	Hispanic <sup>d</sup>
All Malignant Cancers	87.4	91.1	81.2	54.7	60.0	Races	WIIICE	DIACK	API	піврапіс
Leukemia	4.2	4.2	4.2	4.2	4.1					
Lymphoma	12.3	12.5	15.7	6.3	9.8					
Hodgkin Lymphoma	3.4	3.6	3.8	1.5	2.3					
Non-Hodgkin Lymphoma	8.9	8.9	12.0	4.8	7.5					
Brain and Other Nervous System	4.0	4.5	2.3	1.9	3.6					
Bones and Joints	0.7	0.7	_	_	0.7					
Soft Tissue including Heart	2.2	2.1	3.7	1.3	2.0					
Skin excluding Basal and Squamous	11.1	13.2	1.8	_	2.1					
Respiratory System	4.2	4.0	4.9	4.2	2.0					
Male Genital System	12.4	14.4	4.9	3.7	7.8					
Digestive System	15.2	14.4	18.2	17.7	12.7					
			Inciden	ce				Mortali	EV	
	All					All				
Females	Races	White	Black	APIc	Hispanic <sup>d</sup>	All Races	White	Black	API°	Hispanic <sup>d</sup>
Females All Malignant Cancers		White 169.5			Hispanic <sup>d</sup>		White			Hispanic <sup>d</sup>
All Malignant Cancers	Races 164.7	169.5	Black 148.4	API° 134.4	131.6		White			Hispanic <sup>d</sup>
All Malignant Cancers Leukemia	Races 164.7 3.0	169.5 3.1	Black 148.4 2.3	API <sup>c</sup> 134.4 2.6	131.6		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia  Lymphoma	Races 164.7 3.0 8.2	169.5 3.1 8.3	Black 148.4 2.3 10.1	API <sup>c</sup> 134.4 2.6 4.8	131.6 3.0 6.3		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia  Lymphoma  Hodgkin Lymphoma	Races 164.7 3.0 8.2 2.8	169.5 3.1 8.3 3.0	Black 148.4 2.3 10.1 2.9	API <sup>c</sup> 134.4 2.6 4.8 1.4	131.6 3.0 6.3 1.7		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma	Races 164.7 3.0 8.2 2.8 5.4	3.1 8.3 3.0 5.3	Black 148.4 2.3 10.1 2.9 7.3	API° 134.4 2.6 4.8 1.4 3.4	131.6 3.0 6.3 1.7 4.6		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Brain and Other Nervous System	Races 164.7 3.0 8.2 2.8 5.4 3.3	3.1 8.3 3.0 5.3 3.7	Black 148.4 2.3 10.1 2.9 7.3 1.9	API° 134.4 2.6 4.8 1.4 3.4 1.8	131.6 3.0 6.3 1.7 4.6 2.5		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Brain and Other Nervous System Bones and Joints	Races 164.7 3.0 8.2 2.8 5.4 3.3 0.5	3.1 8.3 3.0 5.3 3.7 0.5	Black 148.4 2.3 10.1 2.9 7.3 1.9	API° 134.4 2.6 4.8 1.4 3.4 1.8	131.6 3.0 6.3 1.7 4.6 2.5		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Brain and Other Nervous System Bones and Joints Soft Tissue including Heart	Races 164.7 3.0 8.2 2.8 5.4 3.3 0.5 2.0	169.5 3.1 8.3 3.0 5.3 3.7 0.5 2.0	Black 148.4  2.3 10.1 2.9 7.3 1.9 - 2.7	API° 134.4 2.6 4.8 1.4 3.4 1.8 - 1.7	131.6 3.0 6.3 1.7 4.6 2.5		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Brain and Other Nervous System Bones and Joints Soft Tissue including Heart Skin excluding Basal and Squamous	Races 164.7 3.0 8.2 2.8 5.4 3.3 0.5 2.0 16.1	169.5 3.1 8.3 3.0 5.3 3.7 0.5 2.0 19.4	Black 148.4  2.3 10.1 2.9 7.3 1.9 - 2.7 2.0	API° 134.4 2.6 4.8 1.4 3.4 1.8 - 1.7 1.4	131.6 3.0 6.3 1.7 4.6 2.5 - 2.1 5.0		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Brain and Other Nervous System Bones and Joints Soft Tissue including Heart Skin excluding Basal and Squamous Respiratory System	Races 164.7 3.0 8.2 2.8 5.4 3.3 0.5 2.0 16.1 4.2	169.5  3.1 8.3 3.0 5.3 3.7 0.5 2.0 19.4 4.1	Black 148.4 2.3 10.1 2.9 7.3 1.9 - 2.7 2.0 4.7	API° 134.4 2.6 4.8 1.4 3.4 1.8 - 1.7 1.4 3.7	131.6 3.0 6.3 1.7 4.6 2.5 - 2.1 5.0 2.1		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Brain and Other Nervous System Bones and Joints Soft Tissue including Heart Skin excluding Basal and Squamous Respiratory System Breast	Races 164.7 3.0 8.2 2.8 5.4 3.3 0.5 2.0 16.1 4.2 58.5	169.5  3.1 8.3 3.0 5.3 3.7 0.5 2.0 19.4 4.1 58.0	Black 148.4  2.3 10.1 2.9 7.3 1.9 - 2.7 2.0 4.7 64.4	API° 134.4 2.6 4.8 1.4 3.4 1.8 - 1.7 1.4 3.7 53.5	131.6 3.0 6.3 1.7 4.6 2.5 - 2.1 5.0 2.1 45.2		White			Hispanic <sup>d</sup>
All Malignant Cancers  Leukemia Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Brain and Other Nervous System Bones and Joints Soft Tissue including Heart Skin excluding Basal and Squamous Respiratory System	Races 164.7 3.0 8.2 2.8 5.4 3.3 0.5 2.0 16.1 4.2	169.5  3.1 8.3 3.0 5.3 3.7 0.5 2.0 19.4 4.1	Black 148.4 2.3 10.1 2.9 7.3 1.9 - 2.7 2.0 4.7	API° 134.4 2.6 4.8 1.4 3.4 1.8 - 1.7 1.4 3.7	131.6 3.0 6.3 1.7 4.6 2.5 - 2.1 5.0 2.1		White			Hispanic <sup>d</sup>

Rates are per 100,000.

SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

b US Mortality Files, National Center for Health Statistics, CDC.

c Asian/Pacific Islander

Hispanic is not mutually exclusive from whites, blacks, and Asian/Pacific Islanders. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

<sup>-</sup> Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rates and Trends for the Top 5 Cancer Sites<sup>c</sup> by Age All Races, Both Sexes, 1975-2006

	Incidence			<u>Mortality</u>				
	1975	5-2006		7-2006	1975-2006 199		7-2006	
	Rate	$AAPC^d$	Rate	AAPCd	Rate	AAPC <sup>d</sup>	Rate	$AAPC^d$
Ages 15-19								
All Malignant Cancers	20.0	0.3	20.8	-0.2				
Hodgkin Lymphoma	3.5	-1.1*	3.0	-1.1*				
Brain and Other Nervous System	2.0	0.3	2.0	0.3				
Thyroid	1.6	1.0*	1.8	1.0*				
Non-Hodgkin Lymphoma	1.6	1.7*	1.8	1.7*				
Testis	1.5	1.3*	1.7	1.3*				
Ages 20-24								
All Malignant Cancers	33.4	0.8*	36.4	0.8*				
Hodgkin Lymphoma	5.0	0.7	4.9	2.4*				
Testis	4.3	1.1	4.9	3.0				
Melanoma of the Skin	4.1	1.6*	5.0	1.6*				
Thyroid	3.9	1.4*	4.6	1.4*				
Brain and Other Nervous System	2.2	0.7*	2.4	0.7*				
Ages 25-29								
All Malignant Cancers	54.1	0.7*	56.9	1.1*				
Melanoma of the Skin	7.2	1.4*	8.5	1.4*				
Testis	6.1	1.7*	6.7	2.6				
Thyroid	6.1	1.8*	8.1	4.4*				
Hodgkin Lymphoma	4.9	0.1	4.7	0.1				
Breast	4.0	-0.3	4.0	-0.3				
Ages 30-34								
All Malignant Cancers	83.2	0.5	84.6	-0.3				
Breast	13.2	-0.2	13.2	-0.2				
Melanoma of the Skin	10.3	1.7*	11.1	1.6				
Thyroid	7.6	1.8*	9.9	4.3*				
Testis	6.3	2.0*	7.0	0.1				
Cervix Uteri	6.0	-1.3*	5.3	-1.3*				
Ages 35-39								
All Malignant Cancers	130.2	0.4	129.3	0.0				
Breast	31.4	0.1	30.8	-0.6*				
Melanoma of the Skin	13.6	1.7*		0.1				
Thyroid	9.0	2.5*	12.3	5.0				
Non-Hodgkin Lymphoma	7.9	2.3*	7.7	-2.9*				
Cervix Uteri	7.3	-1.7*	6.0	-2.9"				
CETATY OFEET	1.3	-1./"	0.0	- I . /				

Rates are per 100,000. SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

b

US Mortality Files, National Center for Health Statistics, CDC.
Top 5 cancer sites selected based on 1975-2006 SEER 9 Incidence rates for the age group. d The AAPC is the Average Annual Percent Change and is based on the APCs calculated by

Joinpoint over the time range of 1975-2006. Statistic could not be calculated. Count and rate based on less than 16 cases for the time

interval. AAPC could not be calculated due to insufficient data.

The AAPC is significantly different from zero (p<.05).

SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rates and Trends for the Top 5 Cancer Sites<sup>c</sup> by Age All Races, Males, 1975-2006

	<u>Incidence</u>				<u>Mortality</u>				
	1975	5-2006	1997	7-2006	1975-2006 199		1997	97-2006	
	Rate	AAPC <sup>d</sup>	Rate	AAPCd	Rate	AAPC <sup>d</sup>	Rate	AAPC <sup>d</sup>	
Ages 15-19									
All Malignant Cancers	20.7	0.7*	21.9	0.7*					
Hodgkin Lymphoma	3.3	-1.0*	2.8	-1.0*					
Testis	3.0	1.3*	3.4	1.3*					
Brain and Other Nervous System	2.3	0.3	2.3	0.3					
Non-Hodgkin Lymphoma	1.9	1.5*	2.2	1.5*					
Bones and Joints	1.9	0.4	1.9	0.4					
Ages 20-24									
All Malignant Cancers	32.5	0.6*	33.8	0.1					
Testis	8.5	1.0	9.5	2.7					
Hodgkin Lymphoma	5.0	-0.4	4.6	-0.4					
Melanoma of the Skin	2.8	0.5	3.1	0.5					
Brain and Other Nervous System	2.5	0.2	2.5	0.2					
Non-Hodgkin Lymphoma	2.5	2.0*	3.0	2.0*					
Ages 25-29									
All Malignant Cancers	49.0	0.8*	48.9	0.4					
Testis	12.1	1.6*	13.1	2.4					
Melanoma of the Skin	5.3	0.5	5.7	0.5					
Hodgkin Lymphoma	5.0	-0.3	4.7	-0.3					
Non-Hodgkin Lymphoma	4.3	0.5	4.7	-0.3 -5.6*					
	4.3	-	1.2	-5.0*					
Kaposi sarcoma	4.3	-	1.2	-					
Ages 30-34									
All Malignant Cancers	70.2	0.7	64.9	-0.9					
Testis	12.5	1.9*	13.9	0.0					
Kaposi sarcoma	9.5	-	2.8	-					
Melanoma of the Skin	8.2	0.2	8.0	-0.9*					
Non-Hodgkin Lymphoma	7.4	1.5	6.6	-6.1*					
Hodgkin Lymphoma	4.2	-0.1	4.0	-0.1					
Ages 35-39									
All Malignant Cancers	100.0	0.5	93.0	-0.9					
Melanoma of the Skin	12.0	0.7	11.7	-1.2*					
Kaposi sarcoma	11.5	_	3.9	_					
Non-Hodgkin Lymphoma	11.0	3.3*	9.9	-1.6					
Testis	10.8	2.2*	12.4	0.7					
Colon and Rectum	7.1	1.0*	8.1	1.0*					
332311 dild recodum	,	0	0.1	1.0					

Rates are per 100,000. SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

b

US Mortality Files, National Center for Health Statistics, CDC. Top 5 cancer sites selected based on 1975-2006 rates for the age group. d

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2006.

Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

The AAPC is significantly different from zero (p<.05).

SEER Incidence<sup>a</sup> and U.S. Mortality<sup>b</sup> Rates and Trends for the Top 5 Cancer Sites<sup>c</sup> by Age All Races, Females, 1975-2006

	<u>Incidence</u>				<u>Mortality</u>				
	1975	5-2006		7-2006	1975-2006 199		1997	97-2006	
	Rate	AAPC <sup>d</sup>	Rate	AAPC <sup>d</sup>	Rate	AAPC <sup>d</sup>	Rate	AAPC <sup>d</sup>	
- 15.10									
Ages 15-19	10.0		10 5	0.01					
All Malignant Cancers	19.3	0.3*	19.7	0.3*					
Hodgkin Lymphoma	3.6	-3.4	3.1	-10.1					
Thyroid	2.7	1.1*	3.0	1.1*					
Melanoma of the Skin	1.8	1.2*	2.0	1.2*					
Brain and Other Nervous System	1.7	0.2	1.7	0.2					
0vary	1.5	-0.2	1.4	-0.2					
Ages 20-24									
All Malignant Cancers	34.3	0.9*	39.1	1.5*					
Thyroid	6.7	1.9*	8.2	1.9*					
Melanoma of the Skin	5.4	2.1*	7.0	2.1*					
Hodgkin Lymphoma	5.0	1.1	5.2	-0.6					
Cervix Uteri	2.2	-1.9	1.6	0.4					
Brain and Other Nervous System	1.9	1.6*	2.3	1.6*					
Ages 25-29									
All Malignant Cancers	59.4	0.6*	65.1	1.1*					
Thyroid	10.0	2.0*		4.9*					
Melanoma of the Skin	9.2	1.9*		1.9*					
Breast	8.1	-0.3	8.0	-0.3					
Cervix Uteri	7.5	-1.9		-3.2*					
Hodgkin Lymphoma	4.7	0.6*	4.8	0.6*					
Ages 30-34									
All Malignant Cancers	96.4	0.6*	104.6	1.4*					
Breast	26.3	-0.1	26.7	-0.1					
Melanoma of the Skin	12.3	2.5*	14.3	1.2*					
Thyroid	12.3	2.4*	16.6	4.4*					
Cervix Uteri	12.0	-1.2*	10.7	-1.2*					
Hodgkin Lymphoma	3.7	1.3*	4.2	1.3*					
Ages 35-39									
All Malignant Cancers	160.3	0.6*	165.9	0.9*					
Breast	62.4	0.2	61.6	-0.5*					
Melanoma of the Skin	15.2	2.3	16.9	0.6					
Cervix Uteri	14.5	-1.6*		-1.6*					
Thyroid	14.0	3.7*	19.6	6.1*					
Corpus and Uterus, NOS	6.4	0.6	7.0	3.3*					
	٠								

Rates are per 100,000. SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

b

US Mortality Files, National Center for Health Statistics, CDC. Top 5 cancer sites selected based on 1975-2006 rates for the age group. d

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint over the time range of 1975-2006.

Statistic could not be calculated. Count and rate based on less than 16 cases for the time interval. AAPC could not be calculated due to insufficient data.

The AAPC is significantly different from zero (p<.05).

Table 32.20 SEER 5-Year Relative Survival Rates<sup>a</sup> for the Top 5 Cancer Sites<sup>b</sup> by Age All Races, Both Sexes, 1975-2005

	5-year Relative Survival Rate						
	1975-2005	1975-1982	1983-1990	1991-1998	1999-2005		
<u>Ages 15-19</u>							
All Malignant Cancers	76.1	68.9	76.4	79.3	80.5		
Hodgkin Lymphoma	91.1	88.3	89.1	94.0	95.6		
Brain and Other Nervous System	72.3	62.1	73.6	78.1	76.2		
Thyroid	98.7	98.9	98.9	98.8	98.3		
Non-Hodgkin Lymphoma	69.0	51.4	69.3	72.2	81.1		
Testis	88.6	77.1	91.7	90.1	94.5		
Ages 20-24							
All Malignant Cancers	79.4	74.7	78.4	80.9	84.6		
Hodgkin Lymphoma	89.5	85.0	89.6	91.0	93.2		
Testis	91.6	84.7	90.5	95.0	96.4		
Melanoma of the Skin	91.8	86.2	90.6	94.2	97.2		
Thyroid	99.6	99.6	99.6	99.3	99.5		
Brain and Other Nervous System	64.0	59.1	60.5	71.5	66.4		
Ages 25-29							
All Malignant Cancers	77.6	76.7	74.0	77.3	84.1		
Melanoma of the Skin	92.3	87.8	91.5	94.0	95.5		
Testis	94.4	88.4	95.1	96.2	97.1		
Thyroid	99.7	99.6	99.3	99.9	99.7		
Hodgkin Lymphoma	89.2	85.3	89.1	92.0	90.3		
Breast	72.5	70.2	68.7	73.1	83.1		
Ages 30-34							
All Malignant Cancers	73.5	73.5	68.4	71.8	82.6		
Breast	75.5	70.3	73.1	77.6	82.8		
Melanoma of the Skin	91.5	86.5	90.4	93.4	95.2		
Thyroid	99.7	99.5	99.5	99.8	99.7		
Testis	95.1	92.0	95.6	95.9	95.1		
Cervix Uteri	84.8	84.5	83.1	85.0	87.3		
Ages 35-39							
All Malignant Cancers	71.3	68.0	65.9	71.5	79.9		
Breast	79.9	74.9	76.3	82.7	85.0		
Melanoma of the Skin	91.4	87.5	90.0	92.4	94.7		
Thyroid	99.2	99.0	99.1	99.4	99.0		
Non-Hodgkin Lymphoma	58.9	65.8	51.7	52.7	72.5		
Cervix Uteri	81.4	79.5	80.3	81.4	85.9		

Survival rates are relative rates expressed as percents.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Top 5 cancer sites selected based on 1975-2006 rates for the age group. Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 32.21 SEER 5-Year Relative Survival Rates<sup>a</sup> for the Top 5 Cancer Sites<sup>b</sup> by Age All Races, Males, 1975-2005

	5-year Relative Survival Rate						
	1975-2005	1975-1982	1983-1990	1991-1998	1999-2005		
Ages 15-19							
All Malignant Cancers	71.4	62.3	71.2	75.6	77.1		
Hodgkin Lymphoma	89.9	86.7	87.4	93.1	95.7		
Testis	88.6	77.1	91.7	90.1	94.5		
Brain and Other Nervous System	69.4	58.6	68.3	76.5	75.1		
Non-Hodgkin Lymphoma	66.8	45.3	70.8	70.6	78.0		
Bones and Joints	56.2	42.0	53.6	64.3	63.8		
Ages 20-24							
All Malignant Cancers	74.6	69.4	72.1	76.5	82.1		
Testis	91.6	84.7	90.5	95.0	96.4		
Hodgkin Lymphoma	87.6	83.5	85.8	89.9	93.7		
Melanoma of the Skin	84.5	76.8	82.0	88.2	94.7		
Brain and Other Nervous System	62.5	54.8	58.3	74.2	63.8		
Non-Hodgkin Lymphoma	61.5	54.0	55.5	55.7	80.0		
Ages 25-29							
All Malignant Cancers	70.8	71.3	65.3	69.8	80.4		
Testis	94.4	88.4	95.1	96.2	97.1		
Melanoma of the Skin	94.4 87.6	82.3	95.1 87.1	96.2 89.4	91.8		
	86.9	84.1	87.1	89.4	91.8 89.6		
Hodgkin Lymphoma							
Non-Hodgkin Lymphoma	53.4	57.0	46.4	47.4	72.6		
Kaposi sarcoma	11.9	_	9.0	11.6	40.4		
Ages 30-34							
All Malignant Cancers	64.3	68.6	56.4	60.8	79.0		
Testis	95.1	92.0	95.6	95.9	95.1		
Kaposi sarcoma	15.9	31.3	8.5	19.4	52.1		
Melanoma of the Skin	86.8	79.2	85.1	90.5	92.4		
Non-Hodgkin Lymphoma	49.7	70.0	41.2	39.7	72.2		
Hodgkin Lymphoma	85.1	78.3	83.2	86.8	92.6		
Ages 35-39							
All Malignant Cancers	60.3	59.6	51.9	59.0	73.9		
Melanoma of the Skin	87.0	82.1	85.3	88.4	91.3		
Kaposi sarcoma	15.6	-	6.6	18.8	57.5		
Non-Hodgkin Lymphoma	51.4	62.0	43.9	45.3	66.2		
Testis	95.8	92.1	95.0	96.8	96.8		
Colon and Rectum	60.5	55.6	53.2	60.7	68.9		
JOIOII MIM INCOCUM	00.5	55.0	33.2	00.7	00.7		

Survival rates are relative rates expressed as percents. SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Top 5 cancer sites selected based on 1975-2006 rates for the age group. Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 32.22

SEER 5-Year Relative Survival Rates<sup>a</sup> for the Top 5 Cancer Sites<sup>b</sup> by Age
All Races, Females, 1975-2005

	5-year Relative Survival Rate							
	1975-2005	1975-1982	1983-1990	1991-1998	1999-2005			
<u>Ages 15-19</u>								
All Malignant Cancers	81.2	75.9	82.0	83.4	84.5			
Hodgkin Lymphoma	92.2	89.7	90.7	94.7	95.5			
Thyroid	98.9	98.5	100.0	98.6	98.5			
Melanoma of the Skin	94.3	88.1	94.7	95.0	99.3			
Brain and Other Nervous System	76.6	67.3	80.5	80.3	78.0			
Ovary	88.6	78.5	90.5	91.3	95.4			
Ages 20-24								
All Malignant Cancers	84.1	79.8	85.2	85.2	86.9			
Thyroid	99.5	99.3	99.5	99.6	99.6			
Melanoma of the Skin	95.8	92.1	95.7	96.9	98.3			
Hodgkin Lymphoma	91.4	86.9	93.3	92.1	92.6			
Cervix Uteri	88.4	88.9	90.9	85.0	89.5			
Brain and Other Nervous System	66.3	65.4	63.4	67.1	69.0			
Ages 25-29								
All Malignant Cancers	83.4	80.7	82.2	84.2	87.0			
Thyroid	99.8	99.7	99.4	99.9	99.9			
Melanoma of the Skin	95.1	91.5	94.3	96.6	97.4			
Breast	72.5	70.2	68.5	73.2	83.1			
Cervix Uteri	87.6	88.6	86.4	87.2	88.6			
Hodgkin Lymphoma	91.8	86.9	93.2	94.7	91.1			
Ages 30-34								
All Malignant Cancers	80.2	76.4	78.5	81.2	84.9			
Breast	75.5	70.3	73.1	77.6	82.7			
Melanoma of the Skin	94.8	92.1	94.3	95.3	96.8			
Thyroid	99.7	99.3	99.7	99.8	99.7			
Cervix Uteri	84.8	84.5	83.1	85.0	87.3			
Hodgkin Lymphoma	89.7	85.1	89.9	89.4	94.4			
Ages 35-39								
All Malignant Cancers	78.3	72.3	75.6	80.2	83.4			
Breast	79.8	74.8	76.3	82.7	85.0			
Melanoma of the Skin	95.0	92.2	94.1	95.6	97.2			
Cervix Uteri	81.4	79.5	80.3	81.4	85.9			
Thyroid	99.5	99.3	99.1	99.6	99.3			
Corpus and Uterus, NOS	90.7	92.0	90.4	90.5	90.1			

Survival rates are relative rates expressed as percents.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Do 5 cancer sites selected based on 1975-2006 SEER 9 Incidence rates for the age group.

<sup>-</sup> Statistic could not be calculated due to fewer than 25 cases during the time period.